Special Feature: The Lake Chad Basin: an overlooked crisis?

Humanitarian Exchange Magazine
http://odihpn.org/magazine/the-humanitarian-consequences-of-violence-in-central-america/
Number 70   October 2017

Special Feature: The Lake Chad Basin: an overlooked crisis?
by Humanitarian Practice Network October 2017
The 70th edition of Humanitarian Exchange, co-edited with Joe Read, focuses on the humanitarian crisis in Nigeria and the Lake Chad Basin. The violence perpetrated by Boko Haram and the counter-insurgency campaign in Nigeria, Cameroon, Chad and Niger has created a humanitarian crisis affecting some 17 million people. Some 2.4 million have been displaced, the vast majority of them in north-eastern Nigeria. Many are living in desperate conditions, without access to sufficient food or clean water. The Nigerian government’s focus on defeating Boko Haram militarily, its reluctance to acknowledge the scale and gravity of the humanitarian crisis and the corresponding reticence of humanitarian leaders to challenge that position have combined to undermine the timeliness and effectiveness of the response…

Human Vaccines & Immunotherapeutics (formerly Human Vaccines) Volume 13, Issue 10 2017

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 13, Issue 10 2017
http://www.tandfonline.com/toc/khvi20/current

Article
Cost effectiveness of a practice-based intervention to improve vaccination rates in adults less than 65-years-old
Kenneth J. Smith, Mary Patricia Nowalk, Chyongchiou J. Lin & Richard K. Zimmerman
Pages: 2207-2212
Published online: 22 Aug 2017

Article
Assessment of the potential public health impact of Herpes Zoster vaccination in Germany
Desmond Curran, Desirée Van Oorschot, Lijoy Varghese, Lidia Oostvogels, Tomas Mrkvan, Romulo Colindres, Alfred von Krempelhuber & Anastassia Anastassopoulou
Pages: 2213-2221
Published online: 14 Jul 2017

Commentary
Safety of oral cholera vaccines during pregnancy in developing countries
Ashraful Islam Khan, Md Taufiqul Islam & Firdausi Qadri
Pages: 2245-2246
Published online: 21 Aug 2017

meeting report
The 2017 Keystone Symposium on HIV Vaccines
Christopher A. Cottrell & Andrew B. Ward
Pages: 2348-2351
Published online: 08 Aug 2017

JAMA October 24/31, 2017, Vol 318, No. 16, Pages 1517-1622

JAMA
October 24/31, 2017, Vol 318, No. 16, Pages 1517-1622
http://jama.jamanetwork.com/issue.aspx

Viewpoint
An HIV Vaccine Is Essential for Ending the HIV/AIDS Pandemic
Anthony S. Fauci, MD
JAMA. 2017;318(16):1535-1536. doi:10.1001/jama.2017.13505
In this Viewpoint, Anthony Fauci discusses the limits of current treatment and prevention approaches to the HIV epidemic and proposes that the addition of an HIV vaccine is necessary to slow and end it.

JAMA Guide to Statistics and Methods
Bayesian Analysis: Using Prior Information to Interpret the Results of Clinical Trials
Melanie Quintana, PhD; Kert Viele, PhD; Roger J. Lewis, MD, PhD
JAMA. 2017;318(16):1605-1606. doi:10.1001/jama.2017.15574
This JAMA Guide to Statistics and Methods discusses the Bayesian approach to integrating or updating information from previous studies with newly obtained data to yield a final quantitative summary of the information.

Nature  Volume 550 Number 7677 pp429-554  26 October 2017

Nature 
Volume 550 Number 7677 pp429-554  26 October 2017
http://www.nature.com/nature/current_issue.html

Editorials
Data science can improve aid distribution
Online platforms can help to steer emergency response and ensure money is well spent.

Comment
The Human Cell Atlas: from vision to reality
As an ambitious project to map all the cells in the human body gets officially under way, Aviv Regev, Sarah Teichmann and colleagues outline some key challenges.

Letters
The prevalence of Plasmodium falciparum in sub-Saharan Africa since 1900
Robert W. Snow, Benn Sartorius, David Kyalo, Joseph Maina, Punam Amratia+ et al.
Spatial and temporal modelling of a large dataset of Plasmodium falciparum prevalence rates reveals cycles and trends of malaria transmission in sub-Saharan Africa over a 115 year period.

HIV Drug Resistance — An Emerging Threat to Epidemic Control

New England Journal of Medicine
October 26, 2017  Vol. 377 No. 17
http://www.nejm.org/toc/nejm/medical-journal

HIV Drug Resistance — An Emerging Threat to Epidemic Control
Beyrer and A. Poznia
… A recent report from the WHO, the Global Fund to Fight AIDS, Tuberculosis, and Malaria, and the Centers for Disease Control and Prevention (CDC) showed that the prevalence of HIV drug resistance has increased from 11% to 29% since the global rollout of ART in 2001.1 The report was based on findings from 16 surveys in 14 countries that used the WHO’s recommended approach to population-based sampling for HIV drug resistance among patients in public ART programs, supplemented by data from two population-based HIV impact assessments conducted through the President’s Emergency Plan for AIDS Relief (PEPFAR) in Malawi and Zimbabwe.
It is worrisome that in 6 of 11 countries surveyed — Argentina, Guatemala, Namibia, Nicaragua, Uganda, and Zimbabwe — the rate of pretreatment drug resistance surpassed 10% among people receiving ART for the first time (see graph– Pretreatment HIV Drug Resistance to Nonnucleoside Reverse Transcriptase Inhibitors in 11 Countries.). Here HIV drug resistance was defined as resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs), core drugs in most low- and middle-income countries’ first-line regimens for HIV. Among people with past exposure to ART (those restarting treatment or women with past perinatal exposure) the rate of NNRTI resistance is even higher: 21.6% (95% confidence interval [CI], 13.8 to 32.2).1 A recent report from South Africa revealed that among children 18 months old or younger identified through early infant diagnoses, NNRTI resistance was found in 63.7% (95% CI, 59.0 to 68.4).1
How significant is the increase in resistance to HIV treatment? And what can be done to mitigate it?
 

A CRISPR Way to Diagnose Infectious Diseases

New England Journal of Medicine
October 26, 2017  Vol. 377 No. 17
http://www.nejm.org/toc/nejm/medical-journal

 
Clinical Implications of Basic Research
A CRISPR Way to Diagnose Infectious Diseases
A.M. Caliendo and R.L. Hodinka
A new method for detecting infectious disease involves the use of a genetic probe and an enzyme that is activated once the probe specifically binds the DNA of the pathogen.

The United Nations Material Assistance to Survivors of Cholera in Haiti: Consulting Survivors and Rebuilding Trust

PLOS Currents: Disasters
http://currents.plos.org/disasters/
[Accessed 28 October 2017]

The United Nations Material Assistance to Survivors of Cholera in Haiti: Consulting Survivors and Rebuilding Trust
October 23, 2017 · Brief Report
Introduction: In August 2016, the United Nations (U.N.) Secretary General acknowledged the U.N.’s role in the cholera epidemic that has beset Haiti since 2010. Two months later, the Secretary General issued a historic apology to the Haitian people before the U.N. General Assembly, for the organization’s insufficient response to the cholera outbreak. These steps are part of the U.N.’s “new approach” to cholera in Haiti, which also includes launching a material assistance package for those most affected by cholera.
Methods: This paper draws on the authors’ experience and findings from consultations with more than 60,000 victims and communities affected by disasters and violence in a dozen countries. We reviewed the literature on best practices for consultation with and outreach to communities affected by development and transitional justice programming, and reviewed our own findings from previous studies with a view to identifying recommendations for ensuring that the assistance package reflects the views of people affected by cholera.
Results: The assistance package program is an opportunity to rebuild the relationship between the victims and the United Nations. This can only be achieved if victims are informed and engaged in the process. This consultation effort is also an opportunity to answer a set of key questions related to the nature, structure, and implementation of the victims’ assistance program, but also how the program may be designed to contribute to rebuilding Haitians’ confidence in the U.N. as an institution that promotes peace, human rights, and development.
Discussion: We recommend that the consultations must be accompanied by an outreach effort that provides clear, accurate information on the assistance program, so that it begins to establish a dialogue between the U.N. and cholera victims. Finally, we conclude by offering a number of concrete next steps that the U.N. can take to kick start the consultation process.

Synergistic malaria vaccine combinations identified by systematic antigen screening

PNAS – Proceedings of the National Academy of Sciences of the United States
of America

http://www.pnas.org/content/early/
[Accessed 28 October 2017]

Biological Sciences – Microbiology:
Synergistic malaria vaccine combinations identified by systematic antigen screening
Leyla Y. Bustamante, Gareth T. Powell, Yen-Chun Lin, Michael D. Macklin, Nadia Cross, Alison Kemp, Paula Cawkill, Theo Sanderson, Cecile Crosnier, Nicole Muller-Sienerth, Ogobara K. Doumbo, Boubacar Traore, Peter D. Crompton, Pietro Cicuta, Tuan M. Tran, Gavin J. Wright, and Julian C. Rayner
PNAS 2017 ; published ahead of print October 23, 2017, doi:10.1073/pnas.1702944114

Neuroscience: In search of new concepts

Science         
27 October 2017  Vol 358, Issue 6362
http://www.sciencemag.org/current.dtl
Special Issue: Neuroscience: In search of new concepts

Neuroscience: In search of new concepts
By Peter Stern
Every year, tens of thousands of researchers gather for the Society for Neuroscience meeting. The lecture theaters and poster halls are full of smart and hardworking individuals. Every year, we return home from the conference excited about all the facts learned and insights gained. However, despite the collective efforts of so many bright people, there is still much progress to be made in tackling the big questions in our field. Could it be that we are interpreting our data with outdated concepts? Most of the dominant concepts in present-day neuroscience, after all, were developed 50 to more than 100 years ago.
This special issue questions some of our approaches. Do the many diverse lines of inquiry in neuroscience need a broader set of animal models? How are resources best balanced between big data projects and smaller-scale focused projects?
On the conceptual side, how do we define a brain region—such as, for example, the prefrontal cortex? What is consciousness, and what makes it different from the many unconscious processes in our brain? Why do computers presently lack consciousness, and when might they acquire it?
The concepts of space and time are essential to how we see the world. Neuroscientists should take a fresh look at the emergence of these concepts in the brain and think about how to investigate them.
These are exciting times for neuroscience, but conceptual challenges still remain, as outlined in the Reviews in this issue. With many questions still open, it is time for our community to embrace and address these challenges.

Ethics of maternal vaccination

Science         
27 October 2017  Vol 358, Issue 6362
http://www.sciencemag.org/current.dtl
Special Issue: Neuroscience: In search of new concepts

Policy Forum
Ethics of maternal vaccination
By A. T. Chamberlain, J. V. Lavery, A. White, S. B. Omer
Science27 Oct 2017 : 452-453 Restricted Access
Involvement of women is critical in establishing guidelines
Summary
Innovations in vaccine science have given us an incredible opportunity to leverage the maternal immune system to improve maternal, fetal, and infant health outcomes. Maternal vaccination reduces the risk of infant infection primarily through the transfer of protective maternal antibodies to the fetus (1). Although a growing number of countries are adopting maternal vaccine programs against diseases like influenza and pertussis, and there is an increased focus on including pregnant women in trials for new vaccines, there is little discussion of the ethical underpinnings of maternal vaccine programs (2). We see the proposals thus far as being overly paternalistic, founded on a too-limited conception of risk-benefit analyses that has potential to derail the development and use of lifesaving vaccines. By contrast, an ethical approach focused on mothers’ primary interests in protecting themselves and their children could serve as the basis of the ethical framework that guides vaccine policies.

Evolution-informed forecasting of seasonal influenza A (H3N2)

Science Translational Medicine
25 October 2017  Vol 9, Issue 413
http://stm.sciencemag.org/

Research Articles
Evolution-informed forecasting of seasonal influenza A (H3N2)
By Xiangjun Du, Aaron A. King, Robert J. Woods, Mercedes Pascual
Science Translational Medicine25 Oct 2017 Full Access
A transmission model including virus evolution quantified from genetic sequences produces H3N2 influenza forecasts ahead of the season.

A brief review on the immunological scenario and recent developmental status of vaccines against enteric fever

Vaccine
Volume 35, Issue 47, Pages 6355-6468 (7 November 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/47?sdc=1

Review
A brief review on the immunological scenario and recent developmental status of vaccines against enteric fever
Review Article
Pages 6359-6366
Debaki Ranjan Howlader, Hemanta Koley, Suhrid Maiti, Ushasi Bhaumik, Priyadarshini Mukherjee, Shanta Dutta
Abstract
Enteric fever has been one of the leading causes of severe illness and deaths worldwide. S. Typhi and S. Paratyphi A, B and C are important enteric fever-causing organisms globally. This infection causes about 21 million cases among which 222,000 typhoid related deaths occurred in 2015. These estimates do not reflect the ultimate and real status of the disease due to the lack of unified diagnostic and proper reporting system from typhoid endemic and other regions. Current control strategies have become increasingly ineffective due to the emergence of multi-drug resistance among the strains. This situation worsens the disease-burden in developing as well as in developed countries. Moreover the emergence of S. Paratyphi A as a major enteric fever-causing organism in several Asian countries, demands a prophylactic measure at this hour. Other than two licensed vaccines of S. Typhi, there are no exsisting vaccines for S. Paratyphi A. Moreover, travelers returning from endemic regions are becoming more susceptible to have these infections. In this situation, a need for bivalent approach is required where a single immunogen (consisting from each organism) will be effective against the disease. In this review, we have focused on the general information about typhoidal fever, its spread and epidemiology in brief and the present status of typhoidal vaccines and its future. This review highlights existing gaps in the typhoidal salmonellae research with a special emphasis on the status of present typhoidal salmonellae vaccine research.

A formative research-guided educational intervention to improve the knowledge and attitudes of seniors towards influenza and pneumococcal vaccinations

Vaccine
Volume 35, Issue 47, Pages 6355-6468 (7 November 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/47?sdc=1

Regular papers
A formative research-guided educational intervention to improve the knowledge and attitudes of seniors towards influenza and pneumococcal vaccinations
Original Research Article
Pages 6367-6374
Hanley J. Ho, Yin Ying Chan, Muhamad Alif bin Ibrahim, Anurupa A. Wagle, Christina M. Wong, Angela Chow
Abstract
Background
Adult influenza and pneumococcal vaccination rates in Singapore are low, and factors influencing knowledge and attitudes of seniors towards influenza, pneumonia and their respective vaccines are not well-known. Our study aims to understand the barriers and facilitators towards getting influenza and pneumococcal vaccinations among seniors in Singapore, and subsequently inform the conduct of a relevant community-based educational intervention, as well as evaluate the intervention outcomes.
Methods
We performed a mixed methods study with two components: Firstly, formative research was conducted among community-dwelling seniors, using focus group discussions (FGDs), to understand their knowledge and attitudes towards influenza, pneumonia and their respective vaccines. Next, a quantitative study was conducted to evaluate knowledge of seniors and the effectiveness of an educational intervention.
Results
Four FGDs were organised with 32 participants, who were predominantly female, of lower educational background, and residing in government rental flats. Participants had varying levels of knowledge and many misconceptions about influenza, pneumonia and their respective vaccinations, with concerns about side effects and vaccine effectiveness. The formative research results were used to inform a community-based educational intervention for seniors. Our subsequent evaluation included 604 elderly participants, mainly from lower educational and socio-economic strata, who initially demonstrated poor knowledge scores (median score 5 out of 9, IQR 4-5). Following our intervention, median knowledge score improved to 7 (IQR 6-8) (p < .0001). Significant improvements in knowledge scores were observed across genders, age strata, education levels, and housing types.
Discussion
Our formative research identified knowledge gaps among community-dwelling seniors which affected their attitudes towards vaccination uptake. Key findings were taken into consideration when implementing the educational intervention. Our community-based intervention was effective in improving knowledge and attitudes, and could be used as a cue to action for short-term behaviour changes.

Timeliness of childhood vaccination in the Federated States of Micronesia

Vaccine
Volume 35, Issue 47, Pages 6355-6468 (7 November 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/47?sdc=1

Timeliness of childhood vaccination in the Federated States of Micronesia
Original Research Article
Pages 6404-6411
Ashley Tippins, Andrew J. Leidner, Mehreen Meghani, Aja Griffin, Louisa Helgenberger, Mawuli Nyaku, J. Michael Underwood
Abstract
Background
Vaccination coverage is typically measured as the proportion of individuals who have received recommended vaccine doses by the date of assessment. This approach does not provide information about receipt of vaccines by the recommended age, which is critical for ensuring optimal protection from vaccine-preventable diseases (VPDs).
Objective
To assess vaccination timeliness in the Federated States of Micronesia (FSM), and the projected impact of suboptimal vaccination in the event of an outbreak.
Methods
Timeliness of the 4th dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) and 1st dose of measles, mumps, and rubella vaccine (MMR) among children 24–35 months was assessed in FSM. Both doses are defined as on time if administered from 361 through 395 days in age. Timeliness was calculated by one-way frequency analysis, and dose delays, measured in months after recommended age, were described using inverse Kaplan-Meier analysis. A time-series susceptible-exposed-infected-recovery (TSEIR) model simulated measles outbreaks in populations with on time and late vaccination.
Results
Total coverage for the 4th dose of DTaP ranged from 36.6% to 98.8%, and for the 1st dose of MMR ranged from 80.9% to 100.0% across FSM states. On time coverage for the 4th dose of DTaP ranged from 3.2% to 52.3%, and for the 1st dose of MMR ranged from 21.1% to 66.9%. Maximum and median dose delays beyond the recommended age varied by state. TSEIR models predicted 10.8–13.7% increases in measles cases during an outbreak based on these delays.
Conclusions
In each of the FSM states, a substantial proportion of children received DTaP and MMR doses outside the recommended timeframe. Children who receive vaccinations later than recommended remain susceptible to VPDs during the period they remain unvaccinated, which may have a substantial impact on health systems during an outbreak. Immunization programs should consider vaccination timeliness in addition to coverage as a measure of susceptibility to VPDs in young children.

Using best-worst scaling to rank factors affecting vaccination demand in northern Nigeria

Vaccine
Volume 35, Issue 47, Pages 6355-6468 (7 November 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/47?sdc=1

Using best-worst scaling to rank factors affecting vaccination demand in northern Nigeria
Original Research Article
Pages 6429-6437
Sachiko Ozawa, Chizoba Wonodi, Olufemi Babalola, Tukur Ismail, John Bridges
Abstract
Background
Understanding and ranking the reasons for low vaccination uptake among parents in northern Nigeria is critical to implement effective policies to save lives and prevent illnesses. This study applies best-worst scaling (BWS) to rank various factors affecting parents’ demand for routine childhood immunization.
Methods
We conducted a household survey in Nahuche, Zamfara State in northern Nigeria. Nearly two hundred parents with children under age five were asked about their views on 16 factors using a BWS technique. These factors focused on known attributes that influence the demand for childhood immunization, which were identified from a literature review and reviewed by a local advisory board. The survey systematically presented parents with subsets of six factors and asked them to choose which they think are the most and least important in decisions to vaccinate children. We used a sequential best-worst analysis with conditional logistic regression to rank factors.
Results
The perception that vaccinating a child makes one a good parent was the most important motivation for parents in northern Nigeria to vaccinate children. Statements related to trust and social norms were ranked higher in importance compared to those that highlighted perceived benefits and risks, healthcare service, vaccine information, or opportunity costs. Fathers ranked trust in the media and views of their leaders to be of greatest importance, whereas mothers placed greater importance on social perceptions and norms. Parents of children without routine immunization ranked their trust in local leaders about vaccines higher in considerations, and the media’s views lower, compared to parents with children who received routine immunization.
Conclusions
Framing immunization messages in the context of good parenting and hearing these messages from trusted information sources may motivate parental uptake of childhood vaccines. These results are useful to policymakers to prioritize resources in order to increase awareness and demand for childhood immunization.

Understanding vaccine hesitancy in polio eradication in northern Nigeria

Vaccine
Volume 35, Issue 47, Pages 6355-6468 (7 November 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/47?sdc=1

Understanding vaccine hesitancy in polio eradication in northern Nigeria
Original Research Article
Pages 6438-6443
Sebastian Taylor, Mahmud Khan, Ado Muhammad, Okey Akpala, Marit van Strien, Chris Morry, Warren Feek, Ellyn Ogden
Abstract
Background
Vaccine hesitancy constitutes a major threat to the Global Polio Eradication Initiative (GPEI), and to further expansion of routine immunisation. Understanding hesitancy, leading in some cases to refusal, is vital to the success of GPEI. Re-emergence of circulating wild poliovirus in northern Nigeria in mid-2016, after 24 months polio-free, gives urgency to this. But it is equally important to protect and sustain the global gains available through routine immunisation in a time of rising scepticism and potential rejection of specific vaccines or immunisation more generally.
Methods and findings
This study is based on a purposive sampling survey of 1653 households in high- and low-performing rural, semiurban and urban areas of three high-risk states of northern Nigeria in 2013–14 (Sokoto, Kano and Bauchi). The survey sought to understand factors at household and community level associated with propensity to refuse polio vaccine.
Wealth, female education and knowledge of vaccines were associated with lower propensity to refuse oral polio vaccine (OPV) among rural households. But higher risk of refusal among wealthier, more literate urban household rendered these findings ambiguous. Ethnic and religious identity did not appear to be associated with risk of OPV refusal.
Risk of vaccine refusal was highly clustered among households within a small sub-group of sampled settlements. Contrary to expectations, households in these settlements reported higher levels of expectation of government as service provider, but at the same time lesser confidence in the efficacy of their relations with government.
Conclusions
Results suggest that strategies to address the micro-political dimension of vaccination – expanding community-level engagement, strengthening the role of local government in public health, and enhancing public participation of women – should be effective in reducing non-compliance, as an important set of strategies complementary to conventional didactic/educational approaches and working through religious and traditional ‘influencers’.

County-level assessment of United States kindergarten vaccination rates for measles mumps rubella (MMR) for the 2014–2015 school year

Vaccine
Volume 35, Issue 47, Pages 6355-6468 (7 November 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/47?sdc=1

County-level assessment of United States kindergarten vaccination rates for measles mumps rubella (MMR) for the 2014–2015 school year
Original Research Article
Pages 6444-6450
Sheryl A. Kluberg, Denise P. McGinnis, Yulin Hswen, Maimuna S. Majumder, Mauricio Santillana, John S. Brownstein
Abstract
United States kindergarten measles-mumps-rubella (MMR) vaccination rates are typically reported at the state level by the Centers for Disease Control and Prevention (CDC). The lack of local MMR data prevents identification of areas with low vaccination rates that would be vulnerable to the spread of disease. We collected county-level vaccination rates for the 2014–2015 school year with the objective of identifying these regions.
We requested county-level kindergarten vaccination data from state health departments, and mapped these data to visualize geographic patterns in achievement of the 95% MMR vaccination target. We aggregated the county-level data to the state level for comparison against CDC state estimates. We also analyzed the relationship of MMR vaccination level with county-level and state-level poverty (using U.S. census data), using both a national mixed model with state as a random effect, and individual linear regression models by state.
We received county vaccination data from 43 states. The median kindergarten MMR vaccination rate was 96.0% (IQR 89–98) across all counties, however, we estimated that 48.4% of the represented counties had vaccination rates below 95%. Our state estimates closely reflected CDC values. Nationally, every 10% increase in under-18 county poverty was associated with a 0.24% increase in MMR vaccination rates (95% CI: −0.07%; 0.54%), but the direction of this relationship varied by state.
We found that county data can reveal vaccination trends that are unobservable from state-level data, but we also discovered that the current availability of county-level data is inadequate. Our findings can be used by state health departments to identify target areas for vaccination programs.

Estimating the full public health value of vaccination

Vaccine
Volume 35, Issue 46, Pages 6255-6354 (1 November 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/46?sdc=1

Conference report
Estimating the full public health value of vaccination
Pages 6255-6263
Bradford D. Gessner, David Kaslow, Jacques Louis, Kathleen Neuzil, Katherine L. O’Brien, Valentina Picot, Tikki Pang, Umesh D. Parashar, Mitra Saadatian-Elahi, Christopher B. Nelson
Abstract
There is an enhanced focus on considering the full public health value (FPHV) of vaccination when setting priorities, making regulatory decisions and establishing implementation policy for public health activities. Historically, a therapeutic paradigm has been applied to the evaluation of prophylactic vaccines and focuses on an individual benefit-risk assessment in prospective and individually-randomized phase III trials to assess safety and efficacy against etiologically-confirmed clinical outcomes. By contrast, a public health paradigm considers the population impact and encompasses measures of community benefits against a range of outcomes. For example, measurement of the FPHV of vaccination may incorporate health inequity, social and political disruption, disruption of household integrity, school absenteeism and work loss, health care utilization, long-term/on-going disability, the development of antibiotic resistance, and a range of non-etiologically and etiologically defined clinical outcomes.
Following an initial conference at the Fondation Mérieux in mid-2015, a second conference (December 2016) was held to further describe the efficacy of using the FPHV of vaccination on a variety of prophylactic vaccines. The wider scope of vaccine benefits, improvement in risk assessment, and the need for partnership and coalition building across interventions has also been discussed during the 2014 and 2016 Global Vaccine and Immunization Research Forums and the 2016 Geneva Health Forum, as well as in numerous publications including a special issue of Health Affairs in February 2016.
The December 2016 expert panel concluded that while progress has been made, additional efforts will be necessary to have a more fully formulated assessment of the FPHV of vaccines included into the evidence-base for the value proposition and analysis of unmet medical need to prioritize vaccine development, vaccine licensure, implementation policies and financing decisions. The desired outcomes of these efforts to establish an alternative framework for vaccine evaluation are a more robust vaccine pipeline, improved appreciation of vaccine value and hence of its relative affordability, and greater public access and acceptance of vaccines.

Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage

Vaccine
Volume 35, Issue 46, Pages 6255-6354 (1 November 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/46?sdc=1

Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage
Original Research Article
Pages 6329-6335
Triin Võrno, Katrin Lutsar, Anneli Uusküla, Lee Padrik, Terje Raud, Rainer Reile, Oliver Nahkur, Raul-Allan Kiivet
Abstract
Background
Estonia has high cervical cancer incidence and low screening coverage. We modelled the impact of population-based bivalent, quadrivalent or nonavalent HPV vaccination alongside cervical cancer screening.
Methods
A Markov cohort model of the natural history of HPV infection was used to assess the cost-effectiveness of vaccinating a cohort of 12-year-old girls with bivalent, quadrivalent or nonavalent vaccine in two doses in a national, school-based vaccination programme. The model followed the natural progression of HPV infection into subsequent genital warts (GW); premalignant lesions (CIN 1–3); cervical, oropharyngeal, vulvar, vaginal and anal cancer. Vaccine coverage was assumed to be 70%. A time horizon of 88 years (up to 100 years of age) was used to capture all lifetime vaccination costs and benefits. Costs and utilities were discounted using an annual discount rate of 5%.
Results
Vaccination of 12-year-old girls alongside screening compared to screening alone had an incremental cost-effectiveness ratio (ICER) of €14,007 (bivalent), €14,067 (quadrivalent) and €11,633 (nonavalent) per quality-adjusted life-year (QALY) in the base-case scenario and ranged between €5367–21,711, €5142–21,800 and €4563–18,142, respectively, in sensitivity analysis. The results were most sensitive to changes in discount rate, vaccination regimen, vaccine prices and cervical cancer screening coverage.
Conclusion
Vaccination of 12-year-old girls alongside current cervical cancer screening can be considered a cost-effective intervention in Estonia. Adding HPV vaccination to the national immunisation schedule is expected to prevent a considerable number of HPV infections, genital warts, premalignant lesions, HPV related cancers and deaths. Although in our model ICERs varied slightly depending on the vaccine used, they generally fell within the same range. Cost-effectiveness of HPV vaccination was found to be most dependent on vaccine cost and duration of vaccine immunity, but not on the type of vaccine used.

Would a Two-Dose Rotavirus Vaccine Improve Health Outcomes While Reducing Costs in the Sultanate of Oman?

Value in Health                   
October–November 2017 Volume 20, Issue 9
http://www.valueinhealthjournal.com/current

ISPOR 20th Annual European Congress Research Abstracts
Break out Sessions
Would a Two-Dose Rotavirus Vaccine Improve Health Outcomes While Reducing Costs in the Sultanate of Oman?
X Li, Y Shehata, A Marijam, K Meszaros, S Noibi
Rotavirus is the most common cause of diarrhoea in young children. A recent study in Oman showed no significant disease reductions despite improved healthcare facilities and infection control measures. This study evaluated whether a paediatric vaccination programme with a two-dose Human Rotavirus Vaccine (HRV) would be cost-effective in Oman.

Differences In Vaccine Pricing Between High-Income And Low-Income Markets

Value in Health                   
October–November 2017 Volume 20, Issue 9
http://www.valueinhealthjournal.com/current

Differences In Vaccine Pricing Between High-Income And Low-Income Markets
I Fadeyi, T McLean, F Tavella, L Heron
Published in issue: October-November, 2017
The aim of this study is to evaluate vaccine pricing and the differences in the costs of vaccines between high income (HICs) and low income (LICs) countries.

Cost-Effectiveness of Additional Vaccination of Boys Against HPV In Germany

Value in Health                   
October–November 2017 Volume 20, Issue 9
http://www.valueinhealthjournal.com/current

Cost-Effectiveness of Additional Vaccination of Boys Against HPV In Germany
O Damm, J Horn, B Ultsch, S Scholz, R Mikolajczyk, M Wiese-Posselt, T Harder, O Wichmann, W Greiner
Published in issue: October-November, 2017
Routine vaccination of girls against human papillomavirus (HPV) was introduced in Germany in 2007. In an independently funded model-based study, HPV vaccination of girls was found to be a cost-effective intervention in Germany. However, the cost-effectiveness of vaccinating boys remained unclear, particularly because the previous study did not consider all relevant aspects (i.e. two-dose schedule, broader spectrum of HPV-associated cancers, ninevalent vaccine). The objective of this study was to estimate the cost-effectiveness of adding boys to the existing immunisation strategy in Germany.

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

Hepatology International
First Online: 24 October 2017
Point of View
Mother-to-infant transmission of hepatitis B virus: challenges and perspectives
YF Shih, CJ Liu
Abstract
Chronic hepatitis B virus (HBV) infection due to perinatal mother-to-infant transmission (MTIT) remains a serious global health problem. Despite passive-active immunoprophylaxis using hepatitis B vaccination with or without hepatitis B immunoglobulin (HBIg), up to 8–10% of newborns still acquire HBV infection. Understanding the mechanisms of MTIT is essential for the interruption of HBV transmission. There are three possible routes of transmission: intrauterine transmission, transmission during delivery (intrapartum) and postnatal transmission through close contact or breast milk (postpartum). Overall, positivity for hepatitis B e antigen (HBeAg) and the high viral load of the mothers are the two most important risk factors related to MTIT of HBV. This article briefly reviews the viral factors related to MTIT of HBV and discusses the issues that warrant further investigation.

Journal of AIDS and Clinical Research
2017 Vol.8 No.3 pp.676 ref.21
Regulatory and ethical approval timelines for HIV vaccine studies: an analysis of International AIDS Vaccine Initiative (IAVI) sponsored studies in East and Southern Africa
P Bahati, Z Omungo, B Bender, J Rono – Journal of AIDS and Clinical Research, 2017
Abstract
Background: There has not been a systematic analysis of factors affecting ethics and regulatory timelines of HIV Vaccine trials and epidemiologic studies in Eastern and Southern Africa. We analyzed regulatory and ethics approval timelines and associated factors for HIV vaccine clinical trials and epidemiologic studies in Kenya, Uganda, Rwanda, South Africa and Zambia using data collected from seven Clinical Research Centers (CRCs) from 2001 to 2015.
Methodology: Staff responsible for regulatory issues at CRCs provided archived data on ethical and regulatory review time-frames which were then validated with the sponsor central database. A semi structured questionnaires was administered to establish qualitative information on perceived factors affecting efficiency of approval processes and potential solutions. Quantitative data analysis was conducted using Excel. Qualitative data were analyzed using an open coding to analyze and elicit general themes.
Findings: Data on submission for 23 clinical trials and 51 epidemiological study protocols were analyzed. Across all seven CRCs it took on average of 178 and 108 days to obtain full authorization to commence clinical trials and epidemiological studies, respectively. These timelines are shorter than the average found in other disease fields in Africa but seem longer than approval timelines in the USA and the EU that are estimated at 15-45 days and 43-75 days, respectively. We found that countries with sequential, rather than parallel, submission procedures had longer review timelines. Clinical trial approval timelines that were longer than 200 days were associated with amendment submissions prior to initial approval and with investigational products that required institutional biosafety committee reviews. Lengthier approval timelines were also associated with epidemiological studies with more invasive procedures.
Conclusion: Strategies to further shorten timelines will need to focus on adoption of parallel approval processes; increase frequency of ethical review meetings and capacity strengthening of ethical review institutions.

Media/Policy Watch

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.
 
 
The Atlantic
http://www.theatlantic.com/magazine/
Accessed 28 October 2017
Why Do We Need Separate Chicken-Pox and Shingles Vaccines?
The two diseases are caused by the same virus but strike different groups of people.
Sarah Zhang   Oct 25, 2017
“It’s a real paradigm shift because there are no vaccines that perform so extraordinarily well for people in their 70s and their 80s.”

 
National Geographic
https://www.nationalgeographic.com/magazine/
Accessed 28 October 2017
Here’s Why Vaccines Are So Crucial
If children in poor countries got the shots that rich countries take for granted, hundreds of thousands of young lives could be saved.
By Cynthia Gorney

New York Times
http://www.nytimes.com/
Accessed 28 October 2017
Health
The Long War on Polio, as Recalled by Its Generals
By DONALD G. McNEIL Jr. OCT. 20, 2017
‘Coffee With Polio Experts” will not be picked up by Hulu anytime soon, but there is something compelling in these short videos put out by the Global Polio Eradication Initiative.
The formula is simple: Doctors who have spent years fighting polio in the world’s most remote regions sit down over coffee with a World Health Organization representative to tell war stories.
The production values are amateurish — cups rattle, the bustle of the coffee shop intrudes. But the tales can be gripping, and they are recalled by soldiers who save lives rather than taking them…
 
Washington Post
http://www.washingtonpost.com/
Accessed 28 October 2017
Mom jailed for not vaccinating son doesn’t want future shots
Associated Press · National · Oct 28, 2017
PONTIAC, Mich. — A suburban Detroit mother who served jail time for violating a court order to have her son vaccinated is asking a judge to prevent any future vaccinations.
The Detroit Free Press reports that 40-year-old Rebecca Bredow’s lawyer Clarence Dass says she will have to convince an Oakland County judge that avoiding future vaccinations is “in the best interests of the child.” Bredow opposes vaccines, but her ex-husband, the boy’s father, wants the boy vaccinated.
An Oakland County judge earlier this month sent the Ferndale woman to jail for five days for ignoring a Sept. 27 order to vaccinate the child.
Dass has said in court filings that Bredow “believes that the risks to vaccinations outweigh the benefits.” A judge hasn’t yet scheduled a hearing on Bredow’s latest request.

Vaccines and Global Health: The Week in Review 21 October 2017

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

 pdf version A pdf of the current issue is available here: Vaccines and Global Health_The Week in Review_21 October 2017

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

Milestones :: Perspectives – Dr Mahmoud Fikri

Milestones :: Perspectives
 
Dr Mahmoud Fikri
WHO statement
17 October 2017
Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization announces with great sadness the death of Dr Mahmoud M Fikri, WHO Regional Director for the Eastern Mediterranean.

The Organization extends its sincere condolences to Dr Fikri’s family and his colleagues and friends throughout WHO and the Eastern Mediterranean Region.

Dr Fikri assumed his duties as Regional Director on 1 February 2017. He was on his way to attend the WHO Global Conference on NCDs in Montevideo, Uruguay when he died.

Dr Fikri had previously served as Adviser to the Minister of Health of United Arab Emirates, and had been a prominent regional public health figure for many years.

 

WHO supports the immunization of 874,000 people against yellow fever in Nigeria

WHO supports the immunization of 874,000 people against yellow fever in Nigeria
News release
16 October 2017 | Geneva – The Government of Nigeria has launched a campaign to immunize 873 837 people against yellow fever in the states of Kwara and Kogi.

The ten-day campaign began on Friday, 13 October 2017, and mobilizes more than 200 health workers and volunteers. It targets residents aged 9 months to 45 years old.

“This campaign aims to ensure that people living in high-risk areas are protected from yellow fever, and to prevent the disease from spreading to other parts of the country,” said Dr. Wondimagegnehu Alemu, WHO Nigeria Representative.

WHO has been working with health authorities on its implementation in nine local government areas in Kwara State and two in Kogi State.

Nigeria has requested support from the International Coordination Group (ICG) on vaccine provision for yellow fever. A global stockpile of 6 million doses of the yellow fever vaccine is available for countries to access, with the support of Gavi, the Vaccine Alliance.

WHO and health partners have been supporting the Government’s response to the outbreak since the first case of yellow fever was confirmed in Oke Owa Community, Ifelodun Local Government Area of Kwara state on 12 September.

WHO has deployed experts to Nigeria to support surveillance and investigation, lab testing, public health measures, and engagement with at-risk communities. An Emergency Operations Centre has been activated in the area to coordinate the response.

 

WHO – Subnational immunization coverage data

WHO – Subnational immunization coverage data
140 member states from all WHO regions have shared 2016 subnational data
17 October 2017
In 2017 and for the first time worldwide, WHO has collected and is publishing subnational immunization coverage data reported by its member states. Member states were asked to report their numerator (number of doses administered), denominator (number of eligible individuals) and coverage data (% of eligible individuals receiving the relevant dose of vaccine) for the first and third dose of DTP-containing vaccines (DTP1, DTP3) and measles containing vaccine (MCV1) from their second administrative level (“admin2” often called districts). The data collection is done through the WHO/UNICEF Joint Reporting Form process.

In 2017, 140 member states have shared their subnational data, either from their first subnational administrative level (“admin1”) or admin2 level for DTP1, DTP3 and/or MCV1. Data has been shared for over 20,000 admin1 and/or admin2, and represents about two-third of the total number of surviving infants worldwide. Among them, 94 member states report coverage for DTP3 at admin2 level (bubble charts from 83 of these countries are accessible at the bottom of this page). Of note is that the size of the target population (in the case of DTP3, the number of infants surviving at 12 months of age) of reporting districts varies significantly from a district to another. Indeed the median number of surviving infants in all reported districts is 400, ranging from a population of surviving infants of 1 in the smallest districts to more than 485,000 in the largest (Karachi, Pakistan).

National coverage data often conceals large inequalities in coverage and access within the country, that can be discovered through subnational monitoring. Targeting specific subnational areas with focused interventions will help countries achieve high and equitable coverage and meet their GVAP targets.

WHO and UNICEF are increasing efforts to gather subnational coverage data and support countries in improving the quality and use of the subnational coverage data to take actions to achieve high and equitable immunization coverage.

Resources
Descriptive analysis of subnational data pptx, 7.66Mb
Limitations related to globally reported subnational immunization data pdf, 341kb
Access 83 country visuals for DTP3 at administrative level (data as of 15 July 2017)

Cholera

Cholera
 
Over 700 000 people vaccinated against cholera in Cox’s Bazar
SEAR/PR/1669
Cox’s Bazar, Bangladesh, 20 October 2017 – More than 700 000 people over the age of one year have been administered oral cholera vaccine in the first phase of a campaign here to protect the newly arrived Rohingya population and their host communities against the deadly diarrheal disease.

“The coverage is commendable as the oral cholera vaccination campaign was planned and rolled out against very tight timelines. It demonstrates the commitment of the Ministry of Health, Bangladesh, partners on the ground, as well as partners such as GAVI and the International Coordinating Group on vaccine provision, to help secure the health and wellbeing of these immensely vulnerable people,” said Dr N Paranietharan, WHO Representative to Bangladesh.

The first phase of the oral cholera vaccination (OCV) campaign covered 700 487 people aged one year and above, 179 848 of them children aged between one and five years. The campaign was launched on 10 October to cover 650 000 people. The second phase is scheduled for early November to give an additional OCV dose to children aged between one and five years, for added protection.

“The campaign has successfully vaccinated nearly 180,000 children aged one to five years. We will organize another round for these children to provide them with a second dose that will better protect them against this dangerous disease,” said Edouard Beigbeder, UNICEF Representative in Bangladesh…
 
::::::
::::::
 

Emergencies

Emergencies
 
POLIO
Public Health Emergency of International Concern (PHEIC)
Polio this week as of 18 October 2017 [GPEI]
:: On Tuesday [above], Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, announced with great sadness the death of Dr Mahmoud M Fikri, WHO Regional Director for the Eastern Mediterranean (EMRO) Region. His leadership and dedication to public health, and unwavering support for polio eradication in Syria, Afghanistan and Pakistan will be greatly missed. The GPEI extends its sincere condolences to Dr Fikri’s family and his many colleagues and friends throughout WHO and the EMRO Region.

:: Summary of newly-reported viruses this week:
…Afghanistan: one new wild poliovirus type 1 (WPV1) case reported from Nangarhar province. Two new wild poliovirus 1 (WPV1) positive environmental samples reported, one from Hilmand and one from Kandahar provinces.
Pakistan: three new wild poliovirus 1 (WPV1) positive environmental samples reported, two in Balochistan province and one in Sindh province. See country-specific sections for further details. Syria: four new circulating vaccine derived poliovirus 2 (cVDPV2) cases reported in Deir Ez-Zor governorate, three from Mayadeen district, and one from Boukamal district. One new cVDPV2 positive from a healthy child in Mayadeen district.

::::::

Situation reports on the polio outbreak in Syria
Situation update 17 October 2017
:: Four (4) new cases of cVDPV2 were reported this week— three (3) from Mayadeen district and one (1) from Boukamal district, Deir Ez-Zor governorate.
:: The total number of confirmed cVDPV2 cases is 52.
:: The second immunization round for Raqqa concluded on 13 October. According to administrative data, a total of 144,414 children aged 0-59m were vaccinated with mOPV2. The numbers of children reported vaccinated represented 96% of a revised estimated target calculated according to updated micro-plans.
:: IPV is being administered to children aged between 2-23 months in 2 districts, Raqqa and Thawra. The campaign in Raqqa and Thawra is ongoing.
:: 540,000 Aqua tabs were distributed to families together with vaccination in areas of Rural Raqqa (Salhabiyah, Khilah, Al-Rasheed camp, Hesha, Karama town and camp) during the second Raqqa campaign.
:: New areas were reached this round in the Thawra desert, where 4,550 children (representing 65% of the target) under 5 were vaccinated after a gap of 18 months.

::::::
::::::

WHO Grade 3 Emergencies  [to 21 October 2017]
The Syrian Arab Republic
:: WHO health supplies revive weakened health facilities in besieged Deir-Ez-Zor Governorate in Syria
17 October, 2017, Damascus, Syria – A WHO shipment of health supplies delivered through the Syrian Arab Red Crescent to besieged Deir-Ez-Zor governorate in Syria has helped struggling health facilities deliver life-saving health services to thousands of people.
The 14–ton shipment includes medicines for trauma care, treatment of burns, antibiotics; anti-allergens; cardiovascular medicines; and oral rehydration salts. In total, the supplies are sufficient for almost 1800 trauma cases and 260,000 medical treatments…
:: Situation reports on the polio outbreak in Syria
Situation update 17 October 2017
[See Polio above]

Nigeria
WHO supports the immunization of 874,000 people against yellow fever in Nigeria
News release 16 October 2017
[See Milestones above for more detail]
 
South Sudan
Read the latest health situation report pdf, 2.07Mb  13 October 2017
Republic of South Sudan
CHOLERA SITUATION AND RESPONSE UPDATES
13 OCTOBER 2017
Epidemic trends
:: Cholera transmission has continued to decline countrywide with only three counties [Juba,
Budi, and Fangak] reporting cholera cases in the last four weeks [38-41, 2017].
:: In week 41, four out of 13 samples from Juba tested positive for Vibrio cholerae.

::::::
::::::
 
UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 
Iraq
:: Thousands of Families from Kirkuk Are Returning [EN/AR/KU]
(Baghdad, 17 October 2017): In the past 48 hours, an estimated 61,200 people have been displaced in areas around Kirkuk. Humanitarian partners have dispatched mobile health clinics and are providing hot meals and food parcels to families who have fled. In coming days, partners will be providing 3,000 emergency food rations and hygiene items to families sheltering in public spaces.
“Authorities have confirmed that the majority of displaced families from Kirkuk are already returning to their homes in Kirkuk city,” said Ms. Lise Grande, Humanitarian Coordinator for Iraq. “Most of the families who are still displaced are staying with families and host communities.”…

Syrian Arab Republic
:: 19 Oct 2017  North East Syria Dashboard – September 2017
…Up to 7,000 civilians remain trapped in Ar-Raqqa city and face increasingly deteriorating humanitarian conditions and protection concerns. Despite the risks of exposure to mines, snipers and military operations, some civilians have fled.
…Displacements from and within Deir-ez-Zor Governorate continued due to heavy fighting and airstrikes. An estimated 63,902 people have been displaced from 1 September to 8 October.
…The overall protection situation for civilians remains of high concern across north-eastern Syria, with ISIL reportedly actively preventing civilians attempting to flee the area.
…Large influxes of IDPs from Deir-ez-Zor Governorate are straining existing capacities and services in IDP sites resulting in increased protection needs.

::::::

UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.
Ethiopia
:: 20 Oct 2017  Ethiopia HRD 2017: Status Update, 19 October 2017
Since the revision of the Humanitarian Requirements Document (HRD) in August 2017, the humanitarian context in Ethiopia has continued to evolve which has led the Government and humanitarian partners to further adjust the HRD requirements. In the food sector the needs have been revised slightly upwards to accommodate an increase in the number of beneficiaries through the inclusion of 4 million former Productive Safety Net Programme (PSNP) clients in the HRD. In other sectors such as health and nutrition, needs have also continued to increase mainly due to the deteriorating nutrition situation in Somali region, increase in the number of displaced people, as well as the Fall Army Worm (FAW) outbreak that continues to ravage crops throughout the country….
 

WHO & Regional Offices [to 21 October 2017]

WHO & Regional Offices [to 21 October 2017]
 
Latest news
WHO supports containment of rare virus on Uganda-Kenya border
20 October 2017 – WHO is working to contain an outbreak of Marburg virus disease that has appeared in eastern Uganda on the border with Kenya.

Governments commit to reduce suffering and deaths from noncommunicable diseases
18 October 2017 – Heads of State and Government and ministers from around the world today committed to new and bold action to reduce suffering and death from noncommunicable diseases (NCDs), primarily heart and lung diseases, cancers and diabetes, the world’s leading killers.
 
Highlights
Responding to children and adolescents who have been sexually abused
October 2017 – Sexual abuse of children and adolescents is a gross violation of their rights and a global public health problem. It adversely affects the health of children and adolescents. Health care providers are in a unique position to provide an empathetic response to children and adolescents who have been sexually abused.

Evaluation of the election of the Director-General of WHO
October 2017 – The Sixty-fifth World Health Assembly decided, in resolution WHA65.15 (2012), that an evaluation, open to all Member States, will be conducted by the Executive Board within one year from the appointment of the next Director-General of WHO, to assess the efficacy of the revised process and methods for the election of the Director-General, in order to discuss any need for further enhancing fairness, transparency and equity among the Member States of the six regions of WHO.

WHO delivers lifesaving trauma medicines and supplies for victims of Mogadishu blasts
October 2017 – WHO has delivered lifesaving blood supplies and trauma care medicines as part of its emergency response to the bombings in Mogadishu, Somalia on 14 October, in which more than 275 people were killed and more than 300 people severely injured.

Handwashing an affordable way to prevent diseases and save lives
October 2017 – Global Handwashing Day is an opportunity to design, test, and replicate creative ways to encourage people to wash their hands with soap at critical times.

::::::

Weekly Epidemiological Record, 20 October 2017, vol. 92, 42 (pp. 625–648)
:: Recommended composition of influenza virus vaccines for use in the 2018 southern hemisphere influenza season
:: Zoonotic influenza viruses: antigenic and genetic characteristics and development of candidate vaccine viruses for pandemic preparedness
 
::::::
 
WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: South Sudan conducts Joint External Evaluation of Core capacities for International Health Regulation (2005) 20 October 2017
:: WHO supports containment of rare virus on Uganda-Kenya border20 October 2017
:: WHO supports Bayelsa state to rapidly contain outbreak of Monkeypox virus. 20 October 2017
:: WHO facilitates training on contact tracing for health professionals and volunteers on Plague
:: Namibia Continues to invest in Polio Eradication  19 October 2017
:: Monkey pox virus-Sultan dispels rumours linking outbreak to vaccine safety. 18 October 2017
:: Suspected cases from Seychelles test negative for plague  18 October 2017
:: Supporting the mental health needs of frontline responders 18 October 2017
:: WHO supports the immunization of 874 000 people against yellow fever in Nigeria 16 October 2017

WHO Region of the Americas PAHO
:: Governments commit to reduce suffering and deaths from noncommunicable diseases (10/19/2017)

WHO South-East Asia Region SEARO
:: Over 700 000 people vaccinated against cholera in Cox’s Bazar  20 October 2017
[See Cholera above for more detail]

WHO European Region EURO
:: European Region makes huge gains in NCD response, but needs faster progress 19-10-2017
:: Obituary: Dr Mahmoud M. Fikri, WHO Regional Director for the Eastern Mediterranean Region 18-10-2017
:: Using taxes to beat NCDs: success story in Hungary 17-10-2017
:: Giving influenza vaccination a boost among older people 16-10-2017
:: Nurse Gladis leads the way on influenza vaccination in Jönköping, Sweden 16-10-2017

WHO Eastern Mediterranean Region EMRO
:: WHO delivers additional trauma care supplies to patients injured in Mogadishu attacks, Somalia  19 October 2017
:: Tenfold increase in childhood and adolescent obesity in four decades  11 October 2017

 

CDC/ACIP [to 21 October 2017]

CDC/ACIP [to 21 October 2017]
http://www.cdc.gov/media/index.html
Press Release
Thursday, October 19, 2017
CDC updates guidance for infants born to mothers with possible Zika virus infection during pregnancy – Press Release
This update includes information that has become available since the August 2016 release of the previous guidance.

MMWR News Synopsis for October 19, 2017
:: Update: Interim Guidance for the Diagnosis, Evaluation and Management of Infants with Possible Congenital Zika Virus Infection — United States, October 2017
CDC’s updated interim clinical guidance for infants born to mothers with possible Zika virus infection during pregnancy will provide helpful, interpretable information for families and their healthcare providers. The Centers for Disease Control and Prevention (CDC) issued updated interim clinical guidance for health care providers caring for infants born to mothers with possible Zika virus infection during pregnancy. This update includes information that has become available since the August 2016 release of the previous guidance. Zika virus continues to be a public health threat to pregnant women and their infants, although at lower levels than during the recent epidemic in the Americas. The updated guidance is intended to provide helpful, interpretable information for families and their healthcare providers.

HIV Testing, Linkage to HIV Medical Care, and Interviews for Partner Services Among Women — 61 Health Department Jurisdictions, United States, Puerto Rico, and the U.S. Virgin Islands, 2015
To reduce and eventually eliminate HIV infection among women in the United States, HIV testing programs need to improve early linkage to HIV medical care among HIV-positive women who are not in care – even if it is not the first time they are diagnosed with HIV infection. A new analysis showed that six in 10 women who tested positive for HIV infection via CDC-funded HIV tests had already been diagnosed with HIV infection through a previous test. The vast majority (87 percent) of women who were previously diagnosed were not in HIV medical care at the time of testing, suggesting they were never linked to care or had fallen out of care. Black women were significantly less likely than white women to be linked to HIV medical care within 90 days of the current test. HIV testing is essential – not only to identify new infections, but also to link people with new or previous diagnoses to medical care to achieve viral suppression. To reduce and eventually eliminate HIV infection among women in the United States, HIV testing programs need to improve early linkage to HIV medical care among HIV-positive women who are not in care – even if it is not the first time they are diagnosed with HIV infection.

Tdap Vaccination Coverage During Pregnancy — Selected Sites, United States, 2006–2015
Gina DiGravio
Boston University School of Medicine
Tdap vaccination during pregnancy has increased between 2006 and 2017, from <1% in the years before the recommendation to 53% in 2015. However, this coverage is far short of the ACIP recommendation that every woman receive Tdap vaccine during each pregnancy. Since 2012 the Advisory Committee on Immunization Practices has recommended Tdap vaccination during each pregnancy. From 2006 through 2015, Tdap vaccination coverage in pregnant women participating  in the Birth Defects Study of the Slone Epidemiology Center at Boston University increased from <1% before 2010 to 28% in 2013 and reached 53% in 2015. Although Tdap coverage has increased in recent years, Tdap vaccine coverage remains far below the recommendation that every woman be vaccinated during each pregnancy. Increasing vaccination coverage during pregnancy could help reduce the impact of pertussis on infant morbidity and mortality.

Knowledge, Attitudes, and Practices Related to Ebola Virus Disease at the End of a National Epidemic — Guinea, August 2015
Regional variations in Ebola-related KAP in Guinea, after more than one year of a massive epidemic, reinforce the need for targeted health communication strategies during epidemic response. The findings also highlight the importance of health promotion efforts to prevent sporadic transmission or future outbreaks of Ebola, including messages that aim to address misconceptions about transmission and prevention and to address stigma that survivors might face as they recover from a devastating disease, rebuild their lives, and reintegrate into communities. Efforts to improve the public’s knowledge, attitudes, and practices (KAP) about Ebola Virus Disease (Ebola) were important in controlling the 2014–2016 Ebola epidemic in Guinea, Sierra Leone, and Liberia. A national survey conducted in Guinea in August 2015 found regional variations in Ebola-related KAP.  Results suggest that tailoring health communication by region might be more effective than a uniform, national approach. Most participants understood key aspects of Ebola transmission and prevention and intended to use safer burial practices for relatives with suspected Ebola. However, misconceptions about Ebola transmission were widespread, and many participants expressed concern about being near Ebola survivors.

Reporting Deaths Among Children Aged <5 Years After the Ebola Virus Disease Epidemic — Bombali District, Sierra Leone, 2015–2016
Child mortality surveillance in settings with limited vital registration can be strengthened by using multiple data sources, which together capture community and facility deaths. Mortality surveillance and national death reporting are limited in Sierra Leone, a country with one of the highest mortality rates in the world among children ages <5 years. To inform efforts to strengthen surveillance of stillbirths and deaths in children ages <5 years, multiple surveillance streams in Bombali Sebora chiefdom were retrospectively reviewed. Analysis of multiple death reporting streams, including the 1-1-7 phone alert system established during the Ebola virus disease outbreak, improved collection of data about deaths among children ages <5 years and stillbirths. Community-based reporting strategies, such as phone alerts, can be implemented in countries with incomplete death registration to supplement vital events records and strengthen child mortality surveillance.
 

Announcements

Announcements
 
 
BMGF – Gates Foundation  [to 21 October 2017]
http://www.gatesfoundation.org/Media-Center/Press-Releases
OCTOBER 16, 2017
Bill & Melinda Gates Foundation Releases Open-Source Software to Support Efforts that Expand Access to Financial Services in Developing Countries
New code reduces complexity and cost of building payment platforms that connect poor customers to merchants, banks, mobile money providers, governments

EDCTP    [to 21 October 2017]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
18 October 2017
EDCTP requests proposals for conference management services
EDCTP is soliciting proposals from conference management companies for the provision of services for the Ninth EDCTP Forum…

European Medicines Agency  [to 21 October 2017]
http://www.ema.europa.eu/ema/
20/10/2017
Unparalleled access to clinical data – one year on
Over 3,000 clinical documents published, 3,600 registered users and positive stakeholder feedback …

20/10/2017
New action plan to foster development of advanced therapies
Actions address specific challenges identified by stakeholders
… ATMPs are medicines for human use that are based on genes or cells. These therapies offer ground-breaking new opportunities for the treatment of disease and injury. They are particularly important for severe, untreatable or chronic diseases for which conventional approaches have proven to be inadequate.
ATMPs can be classified into four main groups: gene therapy medicinal products, somatic cell therapy medicinal products, tissue engineered medicinal products and combined ATMPs. EMA has received 18 marketing authorisation applications since the ATMP regulation came into force in 2009. Nine products have been approved.
The Agency’s Committee for Advanced Therapies (CAT) plays a central role in the scientific assessment of ATMPs, as it provides the expertise needed to evaluate these medicines. Other initiatives include European Commission research programmes, the innovation offices in the national competent authorities and EMA’s PRIME scheme…

17/10/2017
EMA’s procedural handling of safety review was complete and independent
EMA’s procedural handling of safety review was complete and independent
European Ombudsman concludes her inquiry into the HPV vaccines referral
The European Medicines Agency (EMA) has welcomed the decision from the European Ombudsman which concludes that there was no maladministration by the Agency in the handling of its safety review of human papillomavirus (HPV) vaccines.
The conclusions of this review were that the available evidence does not support that two specific syndromes, complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS) in young women and girls are caused by HPV vaccines. These vaccines are given to prevent infections with the most common types of HPV which can cause cervical cancer, other HPV-related cancers and pre-cancerous conditions.
The procedure was conducted by EMA’s Pharmacovigilance Risk Assessment Committee’s (PRAC) in 2015.
The Ombudsman’s review followed a complaint which expressed concerns about aspects of the PRAC’s handling of the referral procedure.
Following her inquiry into the procedural aspects complained about, the Ombudsman concluded that her inquiry did not identify any procedural issues that could have negatively affected the work and conclusions of the PRAC referral procedure. The examination of scientific evidence was complete and it was independent.
The Ombudsman also considered that EMA’s conflicts of interest policy was fully complied with during the referral procedure on HPV vaccines and that no conflicts of interest were detected.
The Agency welcomes two suggestions made by the Ombudsman to further improve the information on its scientific assessments that it provides to the public and will now explore ways to address these.

European Vaccine Initiative  [to 21 October 2017]
http://www.euvaccine.eu/news-events
19 October 2017
EDUFLUVAC Final Meeting
After four years of collaborative research activities towards the development of a broadly reactive influenza vaccine, the European Commission-funded project EDUFLUVAC will be concluded by the end of October 2017. The EDUFLUVAC partners met for the final project meeting on 09-10 October in Brussels, Belgium to review the results generated and plan for future activities.
Promising pre-clinical results in different animal models have been obtained, but more research is needed to optimise the strategy undertaken by the consortium, which is based on the Epitope Dilution Phenomenon and the use of baculovirus-derived virus-like particles…

16 October 2017
TRANSVAC: European Vaccine Research and Development Infrastructure
Open Call for Vaccine Development Services
 
 
FDA [to 21 October 2017]
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
October 18, 2017 –
FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma
The U.S. Food and Drug Administration today approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Yescarta, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma (NHL).
“Today marks another milestone in the development of a whole new scientific paradigm for the treatment of serious diseases. In just several decades, gene therapy has gone from being a promising concept to a practical solution to deadly and largely untreatable forms of cancer,” said FDA Commissioner Scott Gottlieb, M.D. “This approval demonstrates the continued momentum of this promising new area of medicine and we’re committed to supporting and helping expedite the development of these products. We will soon release a comprehensive policy to address how we plan to support the development of cell-based regenerative medicine. That policy will also clarify how we will apply our expedited programs to breakthrough products that use CAR-T cells and other gene therapies. We remain committed to supporting the efficient development of safe and effective treatments that leverage these new scientific platforms…
 
 
Gavi [to 21 October 2017]
http://www.gavi.org/library/news/press-releases/
16 October 2017
Attack on health facilities puts all Syrian children at risk
Gavi CEO urges all parties in Syria to stop attacks against health facilities following destruction of vaccine stocks and equipment.
 
 
GHIT Fund   [to 21 October 2017]
https://www.ghitfund.org/
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical ·
2017.10.18      
Upcoming Event: GHIT R&D Forum on December 8th

… The 200-person R&D Forum on December 8th will create opportunities for GHIT’s development partners to share project overviews, R&D progress to date, and lessons learned over the past five years. The event offers unique opportunities to engage with scientists and experts across a multitude of organizations, as well as develop new partnerships to further build our community and accelerate global health R&D…
 
 
MSF/Médecins Sans Frontières  [to 21 October 2017]
http://www.doctorswithoutborders.org/news-stories/press/press-releases
Press release
Doctors Without Borders Challenges Pfizer’s Unmerited Patent for Pneumonia Vaccine in Delhi High Court
NEW YORK/NEW DELHI, OCTOBER 13, 2017—The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières(MSF) filed a petition before the High Court of Delhi today to overturn a patent granted to Pfizer pharmaceutical corporation on the pneumococcal conjugate vaccine (PCV).
 
 
NIH  [to 21 October 2017]
http://www.nih.gov/news-events/news-releases
October 18, 2017
Norman Sharpless sworn in as director of the National Cancer Institute
— Succeeds Harold Varmus, M.D., who stepped down in March 2015.

Experts Outline Pathway to a Universal Influenza Vaccine
October 17, 2017 — NIH-Led meeting identifies knowledge gaps, development goals.
Scientists and clinicians from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the California Institute of Technology discuss key considerations for developing a universal influenza vaccine in a meeting report appearing in the October 17 issue of Immunity. The report summarizes discussions from a workshop NIAID held June 28-29, 2017, in Rockville, Maryland, entitled, “Pathway to a Universal Influenza Vaccine.” The workshop brought together U.S. and international experts from academia, industry and government to identify knowledge gaps in influenza research and to set goals to fill these knowledge gaps. NIAID will use the report to develop a strategic plan and research agenda aimed at the development of a universal influenza vaccine.
 
 
PATH  [to 21 October 2017]
http://www.path.org/news/index.php
Announcement | October 18, 2017
Join PATH at the 66th American Society of Tropical Medicine and Hygiene Annual Meeting
PATH experts to share latest research and innovations to tackle malaria and other Neglected Tropical Diseases, underscore critical role of US in global health

UNAIDS [to 21 October 2017]
http://www.unaids.org/en
Update
20 October 2017
Civil society and WFP increasing food security in Ukraine
 
19 October 2017
UNAIDS urges United Republic of Tanzania to implement HIV Prevention 2020 Road Map
 
19 October 2017
Republic of Moldova to fund HIV prevention services for key populations
 
18 October 2017
Parliamentarians call for firm action towards ending the AIDS epidemic
 
17 October 2017
ILO’S VCT@WORK has reached 6 million workers

UNICEF  [to 21 October 2017]
https://www.unicef.org/media/
20 October, 2017
Violence in Myanmar driving up to 12,000 Rohingya refugee children into Bangladesh every week – UNICEF
DHAKA, BANGLADESH/GENEVA, 20 October 2017 – Desperate living conditions and waterborne diseases are threatening more than 320,000 Rohingya refugee children who have fled to southern Bangladesh since late August, including some 10,000 who crossed from Myanmar over the past few days, UNICEF said today.

7,000 newborns die every day, despite steady decrease in under-five mortality, new report says
NEW YORK/GENEVA/WASHINGTON, 19 October 2017 – Every day in 2016, 15,000 children died before their fifth birthday, 46 per cent of them – or 7,000 babies – died in the first 28 days of life, according to a new UN report.
 
 
Wellcome Trust  [to 21 October 2017]
https://wellcome.ac.uk/news
News / Published: 19 October 2017
First international awards in new Engagement Fellowships
Wellcome’s Engagement Fellowships for 2017 have been awarded to Sara Kenney, Alok Jha, Anita Shervington and our first international fellows, Elizabeth Kimani and Nabeel Peterson. 
Over the next three years the fellows will explore the topics of comic creation, science journalism, child nutrition, inclusion and equity in science.

::::::
 
 
Industry Watch  [to 21 October 2017]
:: FDA Approves GSK’s Shingles Vaccine with Agenus’ QS-21 Stimulon® Adjuvant
– SHINGRIX containing QS-21 Stimulon® demonstrates remarkable efficacy of greater than 90% in pooled studies against shingles
– Shingles is a major public health issue in the US, impacting as many as 1 in 3 adults over the age of 50 years

LEXINGTON, Mass., Oct. 20, 2017 /PRNewswire/ — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that the US Food and Drug Administration (FDA) granted marketing authorization to GlaxoSmithKline’s (GSK) herpes zoster vaccine, SHINGRIX, containing Agenus’ proprietary immune adjuvant QS-21 Stimulon®. SHINGRIX is indicated for prevention of herpes zoster (also known as shingles) in adults aged 50 years and older. The addition of QS-21 Stimulon helps improve the vaccine’s effectiveness by boosting immune response in older adults who often experience age-related decline in immunity…

:: Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines
– Immuno-oncology collaboration aims to develop up to five cancer vaccines that target neoantigens across multiple tumor types
– CureVac to receive an upfront payment of $50 million and an equity investment of €45 million

INDIANAPOLIS and TÜBINGEN, Germany, Oct. 18, 2017 /PRNewswire/ — Eli Lilly and Company and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVac’s proprietary RNActive® technology. The companies will use messenger RNA (mRNA) technology that targets tumor neoantigens for a more robust anti-cancer immune response…
Under the terms of the agreement, CureVac will receive an upfront payment of $50 million and an equity investment of €45 million. CureVac is also eligible to receive more than $1.7 billion in development and commercialization milestones if all five vaccines are successfully developed, plus tiered royalties on product sales. Lilly is responsible for target identification, clinical development and commercialization. CureVac will be responsible for mRNA design, formulation and manufacturing of clinical supply and retains the option to co-promote the vaccine products in Germany.
CureVac’s proprietary RNActive technology will be used to deliver mRNA that ultimately directs the human immune system to target the encoded neoantigens. These tumor-specific neoantigens instruct the patient’s existing immune system to mount a selective and potent response to eradicate the cancer.

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders

Vaccines and Global Health: The Week in Review has expanded its coverage of new reports, books, research and analysis published independent of the journal channel covered in Journal Watch below. Our interests span immunization and vaccines, as well as global public health, health governance, and associated themes. If you would like to suggest content to be included in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

7,000 newborns die every day, despite steady decrease in under-five mortality, new report says
At current trends, 30 million newborns will die within first 28 days of life between 2017 and 2030
News release
19 October 2017 | NEW YORK/GENEVA/WASHINGTON DC – Every day in 2016, 15,000 children died before their fifth birthday, 46% of them – or 7 000 babies – died in the first 28 days of life, according to a new UN report.

Levels and Trends in Child Mortality 2017, reveals that although the number of children dying before the age of five is at a new low– 5.6 million in 2016, compared with nearly 9.9 million in 2000 – the proportion of under-five deaths in the newborn period has increased from 41% to 46% during the same period.

“The lives of 50 million children under-five have been saved since 2000, a testament to the serious commitment by governments and development partners to tackle preventable child deaths,” said UNICEF Chief of Health, Stefan Swartling Peterson. “But unless we do more to stop babies from dying the day they are born, or days after their birth, this progress will remain incomplete. We have the knowledge and technologies that are required – we just need to take them where they are most needed.”

At current trends, 60 million children will die before their fifth birthday between 2017 and 2030, half of them newborns, according to the report released by UNICEF, the World Health Organization, the World Bank and the Population Division of UNDESA which make up the Inter-agency Group for Child Mortality Estimation (IGME)…
 
 
Levels & Trends in Child Mortality – Report 2017
Estimates Developed by the UN Inter-agency Group for Child Mortality Estimation
PDF:
http://www.childmortality.org/files_v21/download/IGME%20report%202017%20child%20mortality%20final.pdf
CHILD SURVIVAL: KEY FACTS AND FIGURES
:: The world has made substantial progress in reducing child mortality in the past several decades. The total number of under-five deaths dropped to 5.6 (5.4, 6.0)1 million in 2016 from
12.6 (12.4, 12.8) million in 1990 – 15,000 every day compared with 35,000 in 1990.

:: Globally, the under-five mortality rate dropped to 41 (39, 44) deaths per 1,000 live births in 2016 from 93 (92, 95) in 1990 – a 56 (53, 58) per cent decline.

:: Globally, 2.6 (2.5, 2.8) million newborns died in 2016 – or 7,000 every day. Neonatal deaths
accounted for 46 per cent of all under-five deaths, increasing from 41 per cent in 2000.

:: The largest number of newborn deaths occurred in Southern Asia (39 per cent), followed by sub-Saharan Africa (38 per cent). Five countries accounted for half of all newborn deaths: India, Pakistan, Nigeria, the Democratic Republic of the Congo and Ethiopia.

:: The neonatal mortality rate fell by 49 per cent from 37 (36, 38) deaths per 1,000 live births in
1990 to 19 (18, 20) in 2016.

:: Children face the highest risk of dying in their first month of life, at a rate of 19 deaths per
1,000 live births. By comparison, the probability of dying after the first month but before reaching age 1 is 12 and after age 1 but before turning 5 is 11.

:: Progress is slower in reducing neonatal mortality rates than in reducing mortality rates in childrenaged 1–59 months. While neonatal mortality declined by 49 per cent, the mortality in children aged 1–59 months declined by 62 per cent from 1990 to 2016.

:: Disparities in child survival exist across regions and countries: in sub-Saharan Africa, approximately 1 child in 13 dies before his or her fifth birthday, while in the world’s high-income
countries the ratio is 1 in 189. Among newborns in sub-Saharan Africa, about 1 child in 36 dies inthe first month, while in the world’s high-income countries the ratio is 1 in 333.

:: Many lives can be saved if the gaps acrosscountries are closed. If all countries had reached
an under-five mortality rate at or below theaverage rate of high-income countries – 5.3 deaths per 1,000 live births – 87 percent of under-five deaths could have been averted, and almost 5 million children’s lives could have been saved in 2016.

:: If current trends continue with more than 50 countries falling short of the Sustainable Development Goal (SDG) target on child survival,some 60 million children under age 5 will die
between 2017 and 2030 – and half of them will be newborns.

:: If every country achieves the SDG target on child survival by 2030, an additional 10 million lives of children under age 5 will be saved throughout the period 2017–2030 – about half of them will be newborns.

:: Most under-five deaths are caused by diseases that are readily preventable or treatable with
proven, cost-effective interventions. Infectious diseases and neonatal complications are
responsible for the vast majority of under-five deaths globally.

:: The probability of dying among children aged 5–14 was 7.5 (7.2, 8.3) deaths per 1,000 children aged 5 in 2016 – substantially lower than among younger children. Still 1 (0.9, 1.1) million children aged 5–14 died in 2016. This is equivalent to 3,000 children in this age group dying every day. Among children aged 5–14, communicable diseases are a less prominent cause of death than among younger children, while other causes including injuries and
non-communicable diseases become important.

Journal Watch

Journal Watch

   Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

Clinical Therapeutics – October 2017  Volume 39, Issue 10

Clinical Therapeutics
October 2017  Volume 39, Issue 10
http://www.clinicaltherapeutics.com/current

Commentaries
Enhancing the Pediatric Drug Development Framework to Deliver Better Pediatric Therapies Tomorrow
Christina Bucci-Rechtweg
p1920–1932
Published online: August 14, 2017

International Children’s Advisory Network: A Multifaceted Approach to Patient Engagement in Pediatric Clinical Research
Meghan Gwara, Sharon Smith, Christine Woods, Elizabeth Sheeren, Hampton Woods
p1933–1938
Published online: September 21, 2017

Reviews
Roles of Clinical Research Networks in Pediatric Drug Development
Mark A. Turner, Sabah Attar, Saskia N. de Wildt, Gilles Vassal, Laura Mangiarini, Carlo Giaquinto
p1939–1948
Published online: September 21, 2017

Frameworks for Evaluating Medicines in Children
Mark A. Turner, Steven Hirschfeld
p1949–1958
Published online: September 26, 2017

Information overload in consumers of health-related information: a scoping review protocol

JBI Database of Systematic Review and Implementation Reports
October 2017 – Volume 15 – Issue 10
http://journals.lww.com/jbisrir/Pages/currenttoc.aspx

Systematic Review Protocols
Information overload in consumers of health-related information: a scoping review protocol
Lee, Kenneth; Roehrer, Erin; Cummings, Elizabeth
JBI Database of Systematic Reviews and Implementation Reports. 15(10):2457-2463, October 2017.

A Devastating Delay — Zika and the Implementation Gap

New England Journal of Medicine
October 19, 2017  Vol. 377 No. 16
http://www.nejm.org/toc/nejm/medical-journal

Perspective
A Devastating Delay — Zika and the Implementation Gap
Stephanie R. Morain, Ph.D., M.P.H., Susan H. Wootton, M.D., and Catherine Eppes, M.D., M.P.H.
N Engl J Med 2017; 377:1505-1507 October 19, 2017 DOI: 10.1056/NEJMp1707273
[Initial text]
The epidemic of Zika in the Americas and the virus’s effects on fetal development have jolted the U.S. medical community and the broader public. Zika’s relatively recent emergence has necessitated rapid research on its virology and pathogenesis, transmission, clinical manifestations, and diagnosis. The medical community has risen to this challenge admirably. Though a PubMed search for articles about Zika published before the 2015 outbreak in Brazil yielded fewer than 110 results, a similar search in July 2017 yielded more than 3000. The National Institutes of Health has identified several high-priority areas of Zika research, and at least 15 related trials are actively enrolling participants, including several vaccine clinical trials.
Developing knowledge to guide prevention and clinical management of Zika virus disease is critical, and these efforts should continue. However, this focus on knowledge acquisition has overshadowed another critical need — namely, ensuring that new knowledge is disseminated to frontline providers and used to improve care…

Economic benefits of sharing and redistributing influenza vaccines when shortages occurred

PLoS One
http://www.plosone.org/

Research Article
Economic benefits of sharing and redistributing influenza vaccines when shortages occurred
Recurrent influenza outbreak has been a concern for government health institutions in Taiwan. Over 10% of the population is infected by influenza viruses every year, and the infection has caused losses to both health and the economy. Approximately three million free vaccine doses are ordered and administered to high-risk populations at the beginning of flu season to control the disease. The government recommends sharing and redistributing vaccine inventories when shortages occur. While this policy intends to increase inventory flexibility, and has been proven as widely valuable, its impact on vaccine availability has not been previously reported.
Sheng-I Chen
Research Article | published 17 Oct 2017 PLOS ONE
https://doi.org/10.1371/journal.pone.0186418

A systematic review of factors affecting vaccine uptake in young children

Vaccine
Volume 35, Issue 45, Pages 6041-6254 (27 October 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/45?sdc=1

Biosecurity
Reviews
A systematic review of factors affecting vaccine uptake in young children
Review Article
Pages 6059-6069
Louise E. Smith, Richard Amlôt, John Weinman, Jenny Yiend, G. James Rubin
Abstract
Background
Many parents make a conscious decision not to vaccinate their child. Multiple beliefs and perceptions surround this choice. If uptake of routine child vaccination is to increase, public health communications about vaccines must be informed by evidence on the factors affecting uptake.
Method
We conducted a systematic review to investigate psychological, social and contextual factors associated with uptake of routine vaccines in young children. Studies were included if they reported analyses of the association between psychological factors and uptake or included parents’ self-reported reasons for or against vaccination.
Results
Our search identified 9110 citations after deduplication. Sixty-eight citations describing sixty-four studies were included in the review. The quality of the studies was mixed. There is strong evidence for an association between vaccination uptake and: not perceiving vaccines to cause adverse effects; general positive attitudes towards vaccination; positive vaccine recommendations; and perceiving fewer practical difficulties of vaccination. While there was good evidence for an association between vaccination and perceived susceptibility to the illness, evidence for an association between perceived severity of an illness and vaccination was weak. Other factors associated with vaccination include knowledge about the vaccine, social influences and trust in the healthcare profession. Having increased information about the vaccine was associated with vaccination, but the influence of different sources of information needs more research.
Conclusion
Understanding which factors are consistently associated with the decision to vaccinate one’s child is important to identify messages which should be targeted by public health communications about routine child vaccinations.

Association of both consistency and strength of self-reported clinician recommendation for HPV vaccination and HPV vaccine uptake among 11- to 12-year-old children

Vaccine
Volume 35, Issue 45, Pages 6041-6254 (27 October 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/45?sdc=1

Association of both consistency and strength of self-reported clinician recommendation for HPV vaccination and HPV vaccine uptake among 11- to 12-year-old children
Original Research Article
Pages 6122-6128
Lila J. Finney Rutten, Jennifer L. St. Sauver, Timothy J. Beebe, Patrick M. Wilson, Debra J. Jacobson, Chun Fan, Carmen Radecki Breitkopf, Susan T. Vadaparampil, Kathy L. MacLaughlin, Robert M. Jacobson
Abstract
Purpose
We tested the hypotheses that consistency and strength of clinician recommendation of the human papillomavirus (HPV) vaccination would be associated with vaccine delivery rates.
Methods
From October 2015 through January 2016, we conducted a survey of primary care clinicians (n = 227) in Southeastern Minnesota to evaluate clinician behaviors regarding HPV vaccination. The survey response rate was 41.0% (51 clinical sites). We used the Rochester Epidemiology Project, a clinical data linkage infrastructure, to ascertain clinical site-level HPV vaccination rates. We examined associations of clinician self-reports of both the consistency and strength of their recommendations for HPV vaccination for patients aged 11–12 years (n = 14,406) with site-level vaccination rates.
Results
The majority of clinicians reported consistently (always or usually) recommending the HPV vaccine to females (79.0%) and to males (62.2%); 71.9% of clinicians reported strongly recommending the vaccine to females while 58.6% reported strongly recommending to males. Consistency and strength of recommending the HPV vaccine was significantly higher among those practicing in pediatrics and board certified in pediatrics compared to family medicine. Higher rates of initiation (1 dose) [Incidence Rate Ratio (IRR) = 1.05; 95% CI (1.01–1.09)] and completion (3 doses) [IRR = 1.08; 95% CI (1.02–1.13)] were observed among clinical sites where, on average, clinicians more frequently reported always or usually recommending the vaccine for females compared to sites where, on average, clinicians reported recommending the vaccine less frequently. Similarly, higher rates of initiation [IRR = 1.03; 95% CI (1.00–1.06)] and completion [IRR = 1.04; CI (1.00, 1.08)] were observed among sites where clinicians reported strongly recommending the vaccine to females more frequently compared to sites where, on average, clinicians reported strongly recommending the HPV vaccine less frequently; similar associations were observed for male initiation [IRR = 1.05; CI (1.02,1.08)] and completion [IRR = 1.05; 95% CI (1.01, 1.09)].
Conclusions
Consistency and strength of HPV vaccination recommendation was associated with higher vaccination rates.

Media/Policy Watch

Media/Policy Watch

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.
 
The Atlantic
http://www.theatlantic.com/magazine/
Accessed 21 October 2017
Will the World’s Most Worrying Flu Virus Go Pandemic?
There’s good news and bad news.
Ed Yong
Oct 19, 2017

Foreign Policy
http://foreignpolicy.com/
Accessed 21 October 2017
Essay
Yemen’s Humanitarian NightmareThe Real Roots of the Conflict
November/December 2017
Asher Orkaby
 

New York Times
http://www.nytimes.com/
Accessed 21 October 2017
The Long War on Polio, as Recalled by Its Generals
“Coffee With Polio Experts” videos may be amateurish, but they are full of insights explaining why polio eradication has been such a struggle.
October 20, 2017 – By DONALD G. McNEIL Jr – Health – Print Headline: “”

Marburg Hemorrhagic Fever Kills 1 Person in Uganda
One Ugandan has died of Marburg, a highly infectious disease that, like Ebola, manifests as a viral hemorrhagic fever, Uganda’s health minister said Thursday.
October 19, 2017 – By THE ASSOCIATED PRESS – World – Print Headline: “Marburg Hemorrhagic Fever Kills 1 Person in Uganda”

Vaccines and Global Health: The Week in Review_14 October 2017

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

 pdf version A pdf of the current issue is available here: Vaccines and Global Health_The Week in Review_14 October 2017

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

Milestones :: Perspectives

Milestones :: Perspectives
 
Meeting: SAGE Strategic Advisory Group of Experts on Immunization (SAGE)
17 – 19 October 2017
Executive Board Room, WHO Headquarters, Geneva, Switzerland
:: Draft agenda pdf, 110kb  As of 27 September 2017
:: Background documents
 
::::::
::::::
 
Attack on vaccines sets back immunization efforts in eastern Syrian Arab Republic
13 October 2017 | GENEVA – The World Health Organization has received reports of an attack on medical facilities in eastern Syrian Arab Republic that has destroyed the only vaccines cold room in al-Mayadeen district, Deir Ezzor Governorate.

More than 100,000 doses of measles vaccines and 35,000 doses of polio vaccines were stored in these facilities, alongside equipment, syringes, and stocks for all vaccine-preventable childhood diseases.

If confirmed, this would set back the efforts of WHO and health partners to protect the children of Deir Ezzor from preventable childhood diseases, including polio. WHO and local partners have intensified efforts to respond to an outbreak of polio that has affected 48 children in the Syrian Arab Republic since March this year.

“WHO has made strenuous efforts in cooperation with health authorities to deliver vaccines to protect the children living in these areas from disease,” said Elizabeth Hoff, WHO Representative in the Syrian Arab Republic. “We unequivocally condemn these actions. Vaccines are not a legitimate target of war.”

“Until a new cold room is built and the required cold chain equipment — including solar fridges, cold boxes and vaccine carriers — are delivered, this will delay the implementation of routine immunization for vulnerable children in the area,” Hoff added.

WHO has supported 23 polio campaigns since the first outbreak in 2013 and helped to establish 1,148 sentinel sites across the country, of which more than 35% are in hard-to-reach and besieged areas, including al-Mayadeen in Deir Ezzor Govenorate.

The last polio vaccination campaign in Deir Ezzor reached 252,768 children aged 0-59 months.
 
::::::
::::::
 
Experimental Ebola vaccines elicit year-long immune response
October 11, 2017 —
NIH reports final data from large clinical trial in West Africa.
Results from a large randomized, placebo-controlled clinical trial in Liberia show that two candidate Ebola vaccines pose no major safety concerns and can elicit immune responses by one month after initial vaccination that last for at least one year. The findings, published in the October 12 issue of the New England Journal of Medicine, are based on a study of 1,500 adults that began during the West Africa Ebola outbreak. The trial is being conducted by a U.S.-Liberia clinical research collaboration known as the Partnership for Research on Ebola Virus in Liberia (PREVAIL), established in 2014 in response to the request from the Liberian Minister of Health to the U.S. Secretary of Health and Human Services. The trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) and involves scientists and clinicians from Liberia and the United States.

“This clinical trial has yielded valuable information that is essential for the continued development of these two Ebola vaccine candidates and also demonstrates that well-designed, ethically sound clinical research can be conducted during an epidemic,” said NIAID Director Anthony S. Fauci, M.D. “A safe and effective vaccine would be a critically important addition to classical public health measures in controlling inevitable future Ebola outbreaks.”

PREVAIL conducts collaborative biomedical research in accordance with best practices, to advance science, strengthen health policy and practice, and improve the health of people in Liberia and around the world. The partnership launched this first study, PREVAIL 1, in February 2015.  Originally designed to enroll 28,000 volunteers, the trial was scaled back to a Phase 2 study when the decline in new Ebola cases made it impossible to conduct a large efficacy study.
“In Liberia, we have demonstrated to the global community that rigorous scientific research can take place in a developing sub-Saharan African country when a mutually beneficial partnership is developed,” noted Dr. Bernice T. Dahn, Liberia’s Minister of Health. “The work of PREVAIL, ranging from the Ebola vaccine to the Ebola survivor studies, clearly manifest the prospects of such a sustainable partnership and clinical research platform.”

The co-leaders of the trial are Stephen B. Kennedy, M.D., M.P.H., senior research scientist at the University of Liberia-Pacific Institute for Research and Evaluation (UL-PIRE) Africa Center, an infectious disease research center; Fatorma Bolay, Ph.D., director, Public Health and Medical Research at the National Public Health Institute of Liberia; and H. Clifford Lane, M.D., NIAID’s clinical director…
 

An HIV Vaccine is Essential for Ending the HIV/AIDS Pandemic

JAMA
New Online – Published October 9, 2017. doi:10.1001/jama.2017.13505
Viewpoint
An HIV Vaccine is Essential for Ending the HIV/AIDS Pandemic
Anthony S. Fauci, MD1
Today, highly effective modalities of HIV treatment and prevention are available, and these essential tools, if properly implemented, could end the current HIV/AIDS pandemic. Yet, the pandemic continues.1

Most of the major infectious diseases affecting humans, such as smallpox, polio, and yellow fever, have required effective vaccines for their control and in some cases elimination, and so the question arises whether the HIV/AIDS pandemic can be effectively addressed without an HIV vaccine. The answer to that question is not straightforward, but needs to be addressed from both a theoretical and a practical standpoint. Theoretically, the HIV pandemic can be ended without an HIV vaccine. More than 30 highly effective anti-HIV drugs are currently available. When given in combinations of 3 or more, these medications can durably suppress the virus such that patients who are treated soon after infection and continue therapy throughout their lifetime can expect to have an almost-normal life expectancy.

Importantly, effective treatment can reduce the level of virus in a person with HIV so low that it is extremely unlikely that this person will transmit the virus to his or her uninfected sexual partner. This concept is referred to as “treatment as prevention.” Therefore, theoretically, if most or all of the people living with HIV in the world could be identified, accessed, and treated, it would be possible to stop all infections and end the epidemic. People who are uninfected, but whose behavior or life situation puts them at high risk of HIV infection, can take a single pill containing 2 anti-HIV drugs and decrease the likelihood of acquiring HIV infection. This approach—“preexposure prophylaxis” or PrEP—can lower the risk of acquiring HIV through sexual activity by more than 90%, or from injection drug use by more than 70% if the medications are taken consistently.2 Accordingly, if both of these treatment and prevention modalities were effectively implemented throughout the world, the HIV/AIDS pandemic would end.

However, from a practical standpoint, ending the HIV/AIDS pandemic without a vaccine is possible, although it is unlikely. Although an estimated 19.5 million of the estimated 36.7 million HIV-infected people globally are receiving anti-HIV therapy (an extraordinary accomplishment), more than 17 million people are not receiving therapy.1 This leaves a substantial treatment gap. These 17 million people can continue to infect others, allowing the pandemic to be sustained. In addition, although PrEP is highly effective in preventing acquisition of HIV among people at high risk of infection, only a very small percentage of these individuals are actually taking these medications. In the United States, it is estimated that only approximately 10% of people who could benefit from PrEP are actually receiving it,3 and this proportion is much smaller elsewhere in the world.1

The Joint United Nations Programme on HIV/AIDS (UNAIDS) has set an ambitious target to help end the HIV pandemic.1 Called “90-90-90,” the goal for 2020 is to have 90% of HIV-infected people throughout the world know their HIV status, 90% of people diagnosed with HIV receiving anti-HIV treatment, and 90% of people who receive treatment having their virus suppressed to undetectable levels. If successful, the result would be that an estimated 73% of all people in the world with HIV would have undetectable viral levels. Since suppressed viral levels result in a marked reduction in the risk of HIV transmission to other individuals, mathematical models suggest that achieving the 90-90-90 goal would reverse the kinetics and trajectory of global HIV disease such that it would no longer be of pandemic proportions. A recent study in rural Kenya and Uganda demonstrated that implementation of community-based testing and treatment resulted in increased HIV diagnosis, initiation of antiretroviral therapy and viral suppression, and the study communities reached the UNAIDS target within 2 years.4 In addition, some entire countries have been successful in reaching the goal of 73%, largely through the efforts of the President’s Emergency Plan for AIDS Relief and the Global Fund to Fight AIDS, Tuberculosis, and Malaria. However, the global figure for achieving this goal in all countries is just 44%.1 Also, modeling studies have suggested that in certain high-prevalence regions of the world, the geographic dispersion of the infected population, would make it extremely difficult to reach them effectively with HIV treatment.5

The question also arises whether it is economically feasible to end the HIV pandemic in the absence of a vaccine. In this regard, the resource requirements to achieve such a goal are continually increasing. The 19.5 million people currently receiving anti-HIV drugs must be maintained on these medications for the rest of their lives; at the same time, anti-HIV drugs need to be provided to the 17.2 million infected, but untreated people. Furthermore, the estimated 1.8 million people who are newly infected with HIV each year1 also need to be treated. In addition, the cost of providing PrEP and other prevention services to the millions of people who are at risk for HIV infection is substantial. In 2016, UNAIDS estimated that the total investments needed for an adequate treatment and prevention response for HIV in low- and middle-income countries between 2016 and 2030 would amount to approximately $350 billion.6 Against this backdrop, a recent Kaiser Family Foundation and UNAIDS study found that donor-government funding for HIV decreased by 7% in 2016, which represents the lowest funding level since 2010.7

Despite the remarkable gains in the treatment and prevention of HIV infection, development of an effective HIV vaccine will likely be necessary to achieve a durable end to the HIV pandemic. An important question is how effective that vaccine must be. One vaccine tested in a large vaccine trial8 in Thailand reduced the risk of infection by 31%, a figure inadequate to justify licensure of the vaccine. In contrast, other vaccines used in controlling or ending global outbreaks have been much more effective. For example, the measles, polio, and yellow fever vaccines are nearly 100% effective. Given the difficulty for the human immune system to mount a protective response against HIV, it is extremely unlikely that an HIV vaccine will be as effective as those other proven vaccines.

In fact, modeling studies have suggested that if current treatment and prevention efforts are continued and an HIV vaccine that is about 50% effective is developed and deployed, millions of additional new HIV infections could be averted, and the pandemic could slow substantially.9

Despite extraordinary advances in the treatment and prevention of HIV infection, it is theoretically possible to end the HIV epidemic by aggressively and effectively implementing these interventions, although from a practical standpoint this goal would be difficult to achieve. Therefore, development of a moderately effective vaccine together with optimal implementation of existing treatment and prevention modalities could end the current HIV pandemic. Recent advances in HIV vaccine research provide hope that at least a moderately effective vaccine can be developed. It is critical to continue to accelerate a robust research effort in that direction while aggressively scaling-up the implementation of current treatment and prevention tools. To do anything less would lead to failure, which for HIV is not an option.

Reference at title link above

 

Cholera

Cholera
 
World’s second largest oral cholera vaccination campaign kicks off at Rohingya camps in Bangladesh
COX’S BAZAR, Bangladesh, 10 October 2017 – A massive cholera immunization campaign started today near Cox’s Bazar, Bangladesh, to protect newly arrived Rohingya and host communities from the life-threatening diarrheal disease. 900 000 doses of the vaccine have been mobilized and are being delivered by more than 200 mobile vaccination teams, making it the second largest oral cholera vaccination campaign ever.

The campaign, which is led by the Ministry of Health and supported by the World Health Organization (WHO) and UNICEF, is being held in Ukhiya and Teknaf, where more than half a million people have arrived from across the border since August, joining vast numbers already residing in a series of settlements and camps.

The first round of the campaign will cover 650,000 people aged one year and older. The second round will commence on 31 October and will target 250,000 children between one and five years with an additional dose of the vaccine for added protection.

“This is the second largest oral vaccination campaign in the world after Haiti in 2016,” says Edouard Beigbeder, UNICEF Representative in Bangladesh. “Cholera is a dangerous disease, especially among children living in cramped, unhygienic conditions. Prevention is essential.”

In the last week, at least 10,292 cases of diarrhoea have been reported and treated from across the settlements and camps. WHO has warned of the potential for an outbreak of cholera.

UNICEF and WHO are supporting the Ministry of Health with planning, distribution, volunteer orientation, operational costs and monitoring.

“Emergency vaccination saves lives. The risk of cholera is clear and present, and the need for decisive action apparent,” says Dr. N Paranietharan, WHO Representative to Bangladesh. “WHO is committed to mobilizing its full technical and operational capacity to support the Ministry and our partners to protect, promote and secure the health of this immensely vulnerable population.”

In Ukhiya 150 teams have been deployed to vaccinate the target population, while 55 teams have been deployed in Teknaf. Each team is comprised of five members.  Though vaccination can provide life-saving protection against cholera, it supplements but does not replace other traditional cholera control measures such as access to clean water, adequate sanitation and good hygiene.

To help meet present water, sanitation and hygiene needs, UNICEF is working to scale up its interventions and communication on safe practices, and is prepositioning critical supplies for case management. WHO is monitoring water quality and working with the Department of Public Health Engineering to increase local laboratory capacity, has raised an early warning, alert and response emergency surveillance system, and has prepositioned life-saving supplies to ensure a rapid response if and when an outbreak occurs. In addition, the WHO-led Health Sector has supported the Ministry set up diarrhea treatment centres among other response-oriented interventions.

 

Emergencies

Emergencies
 
POLIO
Public Health Emergency of International Concern (PHEIC)
Polio this week as of 4 October 2017 [GPEI]
:: Summary of newly-reported viruses this week:
Syria: one new circulating vaccine derived poliovirus 2 (cVDPV2) case reported, from Mayadeen district, Deir Ez-Zor governorate.  Two new cVDPV2 positives from healthy children, both from Mayadeen district. Afghanistan: two new wild poliovirus 1 (WPV1) positive environmental samples reported in Nangarhar province.
Pakistan: three new wild poliovirus 1 (WPV1) positive environmental samples reported in

::::::
::::::

WHO Grade 3 Emergencies  [to 14 October 2017]
The Syrian Arab Republic
:: WHO responds to critical health needs of displaced populations in Al-Tabqa city, Ar-Raqqa Governorate  18 October 2017
:: Syria cVDPV2 outbreak situation report 17, 10 October 2017
 
::::::
 
WHO Grade 2 Emergencies  [to 14 October 2017]
Myanmar
:: Situation Report 5 – 5 October 2017
 KEY HIGHLIGHTS
:: As of 5 October 2017, cumulative new arrivals in all sites of Ukiah, Tekna, Cox’s Bazar and Ramu was 515,000, of which 198 000 are in makeshift settlements, 225,000 in new spontaneous sites and 92,000 in host communities.
:: At the weekly health sector coordination meeting, the revised humanitarian response plan was shared, targeting 1.2 million people in need and the present requirement across sectors totalling USD 434 million. The health sector is targeting to reach these 1.2 million people in need with USD 48 million.
:: An oral cholera vaccine (OCV) campaign will be rolled out in two phases. 1st dose of OCV vaccination campaign is scheduled for 10-16 October, targeting 650 000 people (new arrival population and host communities) aged 1 year and above including pregnant women. 2 weeks after the first dose, the 2nd dose would be given to children under 5 years of age to be given.
:: Oral cholera vaccination campaign kicks off at Rohingya camps in Bangladesh
 [See Cholera above for more detail]

::::::
::::::
 
UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 
Iraq
:: One year on from the start of the battle for Mosul, hundreds of thousands of civilians need…
(Baghdad, 12 October 2017) One year after the start of the military campaign to retake Mosul from the Islamic State of Iraq and the Levant (ISIL), 673,000 Muslawis are still displaced from their homes; 274,000 are living in 18 camps and emergency sites surrounding the city; 400,000 are staying with family, friends or in rented accommodation.

Syrian Arab Republic
:: 13 Oct 2017  Growing concerns for Syrian civilians amid intense fighting in Al Raqqa and Deir ez-Zor

::::::

UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.
Ethiopia
:: 13 Oct 2017  Ethiopia: Humanitarian Response Situation Report No.14 (August – September 2017)

::::::
::::::
 
Editor’s Note:
We will cluster these recent emergencies as below and continue to monitor the WHO webpages for updates and key developments.

EBOLA/EVD  [to 14 October 2017]
http://www.who.int/ebola/en/
Experimental Ebola vaccines elicit year-long immune response
October 11, 2017 — NIH reports final data from large clinical trial in West Africa.
[See Milestones/Perspectives above for more detail]

MERS-CoV [to 14 October 2017]
http://www.who.int/emergencies/mers-cov/en/
DONs
Middle East respiratory syndrome coronavirus (MERS-CoV) – Saudi Arabia
9 October 2017
Between 31 August and 26 September 2017, the national IHR focal point of Saudi Arabia reported nine additional cases of Middle East Respiratory Syndrome (MERS), including four deaths. In addition, four deaths from previously reported cases were reported…
 

WHO & Regional Offices [to 14 October 2017]

WHO & Regional Offices [to 14 October 2017]
 
WHO to establish commission on noncommunicable diseases
10 October 2017 – Dr Tedros Adhanom Ghebreyesus, the WHO’s Director-General, today announced the establishment of a new High-level global Commission on Noncommunicable Diseases (NCDs). The announcement came at the 64th Session of WHO’s Regional Committee for the Eastern Mediterranean being held in Islamabad, 9-12 October. The commission’s aim is to identify innovative ways to curb the world’s biggest causes of death and extend life expectancy for millions of people.
Read the statement

Sixty-eighth session of the Regional Committee for the Western Pacific
10 October 2017 — The WHO Regional Committee for the Western Pacific today opened its 68th session in Brisbane, Australia. The annual meeting brings together ministers of health and senior officials from 37 countries and areas to decide on issues that affect the health and well-being of the Region’s peoples.

Highlights
Investing in disaster prevention for a healthier world
October 2017 – The International Day for Disaster Reduction (IDDR) reminds us of the importance of putting health at the centre of action to prevent, prepare for, respond to and recover from emergencies and disasters. Millions of people are killed, injured or made sick each year by natural and manmade disasters.

Nepal tackles diabetic retinopathy
October 2017 – Diabetic retinopathy, which contributes to 2.6% of blindness in the world, can be a challenging disease for many countries to manage, because doing so involves two different parts of the health system, that which cares for patients with diabetes and that which cares for patients with vision loss. A lack of coordination can lead to people missing out on essential services, enduring long waits or traveling far from home to receive care.

Progressing the Sustainable Development Goals through Health in All Policies
October 2017 – WHO and the Government of South Australia have published the case study book on Health in All Policies (HiAP), which describes experiences from around the world in the context of the 2030 Sustainable Development Agenda.

WHO scales up response to plague in Madagascar
October 2017 – WHO is rapidly scaling up its response to an outbreak of plague that has spread to the capital and port towns, infecting more than 100 people in just a few weeks.

::::::

Weekly Epidemiological Record, 13 October 2017, vol. 92, 41 (pp. 609–624)
:: Executive summary of the 9th meeting of the WHO working group RT-PCR for the detection and subtyping of influenza viruses
:: Executive summary of the 6th meeting of the WHO Expert Working Group of the GISRS for Surveillance of Antiviral Susceptibility
:: Continuing risk of meningitis due to Neisseria meningitidis serogroup C in Africa: revised recommendations from a WHO expert consultation
:: Progress towards eliminating onchocerciasis in the WHO Region of the Americas: elimination of transmission in the north-east focus of the Bolivarian Republic of Venezuela
 
::::::
 
5 October 2017
GIN September 2017 pdf, 2.74Mb
 
::::::
 
WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: With USAID’s support, WHO strengthens integrated diseases surveillance and response for timely and effective public health action in South Sudan  13 October 2017
:: WHO Regional Director for Africa begins official visit to Nigeria  11 October 2017
:: The World Mental Health Day commemorated in South Sudan  11 October 2017

WHO Region of the Americas PAHO
:: Eradicating hunger in Latin America and the Caribbean by 2030 is becoming increasingly unlikely (10/10/2017)

WHO South-East Asia Region SEARO
:: WHO, partners implement 900 000 dose oral cholera vaccination campaign in Cox’s Bazaar  10 Oct 2017

WHO European Region EURO
:: World Obesity Day: Understanding the social consequences of obesity 10-10-2017
:: “We’re doctors but we’re also human”: helping Syrian health workers handle severe stress 09-10-2017

WHO Eastern Mediterranean Region EMRO
:: 64th session of the Regional Committee for the Eastern Mediterranean concludes in Pakistan
12 October 2017, Islamabad, Pakistan – Members of WHO’s Regional Committee for the Eastern Mediterranean today concluded their 64th Session, endorsing a number of resolutions that will have a positive impact on the health of populations in countries of the Eastern Mediterranean Region.
Among the topics discussed were cancer, climate change, the health of adolescents and antimicrobial resistance…

WHO Western Pacific Region
:: Countries pledge to fund priority public health services; make medicines, the health workforce and food safer
BRISBANE, Australia, 12 October 2017 – Governments from across the Region today pledged to take action to ensure the safety of medicines and competence of health workers. They also agreed on frameworks for the financing of priority health services and for making food safer. Ministers and senior officials at the 68th session of the World Health Organization (WHO) Regional Committee for the Western Pacific also noted progress in areas of public health including: noncommunicable diseases, tobacco control, mental health, tuberculosis (TB), hepatitis, traditional medicine, and gender and health…
:: World Health Organization Director-General Dr Tedros appoints Cook Islands’ Elizabeth Iro as WHO’s Chief Nursing Officer
BRISBANE, Australia, 12 October 2017 – Director-General Dr Tedros Adhanom Ghebreyesus today appointed Ms Elizabeth Iro as the Chief Nursing Officer at the World Health Organization (WHO). Ms Iro is a registered nurse, and the Cook Islands’ current Secretary of Health. With this announcement, Dr Tedros fulfils a commitment he made during his transition to the Director-General role to appoint a nurse to his senior team. “I am thrilled to welcome Ms Iro to our team as WHO’s Chief Nursing Officer,” said Dr Tedros.
 

CDC/ACIP [to 14 October 2017]

CDC/ACIP [to 14 October 2017]
http://www.cdc.gov/media/index.html

MMWR News Synopsis for October 12, 2017
:: Vaccination Coverage Among Children in Kindergarten — United States, 2016–2017 School Year
Getting vaccines at the recommended ages protects children from serious vaccine-preventable diseases before they start school. For the 2016-2017 school year, vaccination coverage among kindergartners remained high. Immunization programs conduct annual kindergarten vaccination assessments to monitor school entry vaccination coverage. For the 2016-17 school year, vaccination coverage among kindergartners remained high and exemptions remained low. Based on the data:
:: Median vaccination coverage was 94.0 percent for two doses of measles, mumps, and rubella vaccine; 94.5 percent for the state-required number of doses of diphtheria, tetanus, and acellular pertussis vaccine; and 93.8 percent for two doses of varicella vaccine.
:: Median exemption level was 2.0 percent.
:: Median proportion of kindergartners under a grace period or provisional enrollment was 2.0 percent, the same as in 2015–16.
School assessment allows immunization programs to focus on schools with lower vaccination coverage and higher exemption levels, and encourages follow up with undervaccinated students to ensure kindergartners are protected from vaccine-preventable diseases.